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Abstract I 
Abstract 
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is a 
ligand-activated transcription factor that regulates the immunogenicity of myeloid cells 
such as dendritic cells (DCs), macrophages, and microglia. In this thesis, we 
investigated two novel aspects of PPARγ-mediated modulation of immune responses.  
First, we characterised the impact of PPARγ activation on cross-presentation of soluble 
antigen by DCs and subsequent cross-priming of naive CD8+ T cells. We demonstrated 
that treatment with the synthetic PPARγ agonist PIO significantly increased MR 
expression in DCs in vitro and in vivo which in turn resulted in enhanced MR-mediated 
uptake of the soluble model antigen OVA and elevated levels of cross-presented OVA. 
Importantly, after PPARγ-activation, DCs significantly upregulated the coinhibitory 
molecule B7H1 which impaired activation of naive CD8+ T cells and resulted in 
strongly reduced CD8+ T cell effector functions. Importantly, these data unveil a new 
mechanism of antigen-specific CD8+ T cell inactivation by DCs that results from 
increased cross-presentation and concomitant coinhibitory signalling via B7H1. 
In the second part of this thesis, we revealed that during the effector phase of 
experimental autoimmune encephalomyelitis (EAE), PPARγ limits myeloid cell-
mediated autoimmune inflammation. We identified CCR2+Ly-6Chi inflammatory 
monocytes as the key myeloid cell population regulated by PPARγ and showed that a 
distinct population of inflammatory monocytes differentiated into microglial cells after 
infiltration of the central nervous system (CNS). PPARγ-mediated modulation of CNS 
myeloid cell immunogenicity resulted in dampening of both directions of myeloid cell – 
encephalitogenic CD4+ T cell interaction. Firstly, activation of PPARγ in CNS 
macrophages and microglia reduced the expression of MHC-II and CD40, both of 
which are important for local reactivation of autoreactive T cells. In line with this, we 
observed that TH1 and TH17 responses were diminished in the CNS. Secondly, PPARγ 
activation in myeloid cells increased the threshold towards T cell-mediated licensing 
resulting in reduced T cell-induced innate immune responses, i.e. production of nitric 
oxide or tumor necrosis factor-alpha. Hence, these data demonstrate that modulation of 
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myeloid cell immunogenicity during ongoing CNS inflammation is a very effective 
strategy to interefere with reciprocal interaction of autoreactive T cells and CNS 
myeloid cells which critically contributes to cessation of CNS autoimmunity.  
Taken together, the studies presented in this thesis identify PPARγ in myeloid cells as a 
promising candidate for the development of therapeutic approaches aimed at the control 
of excessive autoimmune responses. Importantly, we provide evidence that targeting 
PPARγ in myeloid cells interferes with ongoing inflammation in multiple aspects, 
namely with T cell priming and/or local reactivation but also with T cell-mediated 
licensing of myeloid cells.  
 
 
 
 
Zusammenfassung III 
Zusammenfassung 
Der nukleäre Peroxisom-Proliferator-aktivierte Rezeptor gamma (PPARγ) ist ein durch 
Liganden aktivierter Transkriptionsfaktor, der die Immunogenität von myeloiden 
Zellen, wie zum Beispiel dendritischen Zellen (DZ), Makrophagen und Mikroglia 
reguliert. In der vorliegenden Arbeit wurden zwei bislang unbekannte Aspekte der 
PPARγ-vermittelten Modulation von Immunantworten untersucht.  
Im ersten Teil der Arbeit konnten wir zeigen, dass PPARγ die Fähigkeit von DZ zur 
Kreuzpräsentation von löslichem Antigen und die anschließende Aktivierung von 
naiven CD8+ T Zellen reguliert. Die Aktivierung von PPARγ in DZ durch den 
synthetischen Liganden PIO führte zu einer signifikant erhöhten Expression des 
Mannoserezeptors (MR) in vitro und in vivo, was in einem Anstieg sowohl der MR-
vermittelten Aufnahme des löslichen Modellantigens Ovalbumin (OVA) als auch der 
Menge an kreuzpräsentiertem OVA resultierte. Weiterhin konnte beobachtet werden, 
dass eine PPARγ-Aktivierung in DZ eine starke Hochregulation des koinhibitorischen 
Moleküls B7H1 induzierte, welche die Aktivierung von naiven CD8+ T Zellen und 
deren Differenzierung in Effektorzellen verhinderte. Zusammenfassend lässt sich sagen, 
dass in dieser Studie ein neuer Mechanismus der antigen-spezifischen CD8+ T Zell-
Inaktivierung durch DZ aufgezeigt werden konnte, der durch die Kombination aus 
erhöhter Kreuzpräsentation mit gleichzeitiger Hochregulation des koinhibitorischen 
Moleküls B7H1 vermittelt wird.  
Im zweiten Teil dieser Arbeit konnte gezeigt werden, dass PPARγ in myeloiden Zellen 
während der Effektorphase der experimentellen autoimmunen Enzephalomyelitis (EAE) 
eine wichtige Rolle spielt, da PPARγ die durch myeloide Zellen verursachte 
autoimmune Entzündungsreaktion hemmt. Des Weiteren konnten wir zeigen, dass die 
Population der CCR2+Ly-6Chi inflammatorischen Monozyten die zentrale myeloide 
Zellpopulation darstellt, die durch PPARγ reguliert ist und dass inflammtorische 
Monozyten nach Einwanderung ins zentrale Nervensystem (ZNS) zu Mikroglia 
differenzieren können. Die PPARγ-vermittelte Modulation der Immunogenität von 
myeloiden Zellen des ZNS führte zu einer Abschwächung beider Richtungen der 
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Interaktion von myeloiden und enzephalitogenen T Zellen. Zum Einen reduzierte die 
Aktivierung von PPARγ in myeloiden Zellen die Expression von MHC-II Molekülen 
und CD40, die bei der lokalen Reaktivierung von autoreaktiven T Zellen eine wichtige 
Rolle spielen, und wir konnten zeigen, dass gleichzeitig die TH1 und TH17 Antworten 
im ZNS reduziert waren. Auf der anderen Seite erhöhte die Aktivierung von PPARγ in 
myeloiden Zellen die Reizschwelle gegenüber T Zell-vermittelter Aktivierung, was zu 
einer Reduktion der T Zell-induzierten innaten Immunantworten, wie z.B. der 
Produktion von Stickoxid und Tumornekrosefaktor-alpha, führte. Zusammengenommen 
zeigen diese Daten, dass die Modulation der Immunogenität von myeloiden Zellen 
während einer Inflammation des ZNS einen sehr effektiven Ansatz darstellt, um die 
wechselseitige Aktivierung von myeloiden Zellen und enzephalitogenen T Zellen zu 
hemmen.  
Die hier präsentierten Studien zeigen auf, dass die Aktivierung von PPARγ in 
myeloiden Zellen einen erfolgversprechenden Ansatz für die Entwicklung von 
Therapien ist, die die Behandlung von Autoimmunerkrankungen zum Ziel haben. Ein 
wichtiger Aspekt, der in dieser Arbeit gezeigt werden konnte, ist, dass die Aktivierung 
von PPARγ in myeloiden Zellen in mehrerer Hinsicht abschwächend auf anhaltende 
Inflammation wirkt: Zum einen hemmt es T Zell (Re-)Aktivierung, zum anderen 
verhindert es die durch T Zellen vermittelte Aktivierung von myeloiden Zellen. 
 
 
  
1  Introduction 1 
1 Introduction 
1.1 The immune system 
The mammalian immune system is responsible for the host defence against invading 
pathogens and is traditionally divided into two parts, namely the innate and the adaptive 
immune system1. While the innate immune system is highly conserved among species, 
only vertebrates are able to mount antigen-specific and long-lasting adaptive immunity2. 
The innate immune system is the first line of host defence and includes cellular and 
biochemical defense mechanisms that are in place before infection and mediate fast 
activation of the innate immune response after exposure to pathogens. In contrast, the 
highly specific adaptive immune system is involved in the elimination of the infection at 
a later phase of the immune response as antigen-specific clones first need to proliferate 
and differentiate into effector cells before they can mediate protection. Furthermore, the 
adaptive immune system is involved in the generation of immunological memory3.   
1.1.1 The innate immune system  
The innate immune system consists of several distinct components that are rapidly 
activated after exposure to pathogens and limit the infection. These components 
include: 
• Epithelial surfaces, e.g. the skin or mucosal epithelia, which function as physical 
barriers to prevent intrusion of microbes2. 
• Circulating cells, including dendritic cells (DCs) or macrophages, which are 
important for detection and elimination of pathogens2. 
• Soluble mediators which include peptides that act as natural antibiotics, members 
of the complement system that play a role in opsonisation and lysis of 
microorganisms, as well as cytokines that regulate and coordinate the activity of 
innate as well as adaptive immune cells3.  
Cells of the innate immune system express germ line-encoded pattern-recognition 
receptors (PRRs) that recognise conserved structures expressed by many 
microorganisms. Although these pathogen-associated molecular patterns (PAMPs) are 
distinct with regard to their chemical structure, all share some general characteristics. 
1  Introduction 2 
Firstly, they are only produced by pathogens and not by the host. Secondly, PAMPs are 
often essential for the survival or pathogenicity of the microorganism. Thirdly, 
structures are invariant and common to many pathogens1. Upon recognition of a PAMP 
by its specific PRR, the PRR-expressing cell becomes activated and performs effector 
functions, like phagocytosis or activation of proinflammatory signalling pathways 
resulting in production of proinflammatory cytokines like interleukin-6 (IL-6), IL-12, or 
tumor necrosis factor-alpha (TNF-α). Furthermore, the production of nitric oxide (NO) 
or reactive oxygen species (ROS) contributes to efficient clearance of phagocytosed 
pathogens2-4. 
DCs are professional antigen-presenting cells (APCs) that represent a critical link 
between innate and adaptive immunity as they play a central role in the activation and 
differentiation of naive T lymphocytes which belong to the adaptive immune system. 
Immature DCs are present in most tissues where they act as sentinels, continuously 
sampling the environment. Upon encounter with a powerful immunological stimulus, 
e.g. the recognition of PAMPs by PRRs5, the DC matures which leads to phenotypical 
and functional changes that are the prerequisite for the activation of antigen-specific 
T cells. During maturation, DCs loose the ability to take up and process antigen from 
the environment while the surface expression levels of molecules important for effective 
T cell activation are upregulated, namely major histocompatibility complexes (MHC) 
and the costimulatory molecules CD80, CD86, and CD406. Furthermore, the expression 
of chemokine receptors (CCRs), which are responsible for homing to peripheral tissues, 
are downregulated and the expression of CCR7 is upregulated7. Expression of CCR7 
mediates DC migration towards and entry into the T cell areas of secondary lymphoid 
organs which allows close contact of antigen-presenting DCs with naive T cells. 
Recognition of the specific antigen complexed to the MHC molecule results in 
activation of the T cell8. 
1.1.2 The adaptive immune system  
The adaptive immune response is divided into a B cell-mediated humoral and a T cell-
mediated cellular immune response3. Every B and T cell, respectively, carries a unique, 
highly antigen-specific receptor on the surface that is not germ line-encoded but 
generated during the development of each cell by a process termed somatic 
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recombination1,2. The B cell receptor (BCR) is expressed membrane-bound or as its 
soluble form, the antibody, and recognises diverse three-dimensional structures. 
Extracellular microbes and their toxins are targets of the humoral immune response. 
Binding of foreign antigens by antibodies and subsequent recognition of these 
complexes by innate immune cells results in activation and induction of effector 
mechanisms like phagocytosis or production of proinflammatory cytokines in these 
cells3. 
The cellular immune response is mediated by T lymphocytes and is important for the 
clearance of infections with intracellular pathogens. In contrast to the BCR, the T cell 
receptor (TCR) recognises its specific antigen only as antigen-derived peptide presented 
on MHCs on the surface of APCs. T cells are divided into CD4+ and CD8+ T cells which 
carry out different effector functions and recognise peptides in the context of different 
MHC molecules. CD4+ T cells recognise peptides bound to MHC class II molecules 
(MHC-II) and differentiate into T helper cells which play an important role in full 
activation of B cells and in licensing of DCs to activate naive CD8+ T cells. In contrast, 
CD8+ T cells respond to peptides in the context of MHC class I molecules (MHC-I) and 
differentiate into cytotoxic T lymphocytes that efficiently eliminate infected cells3,9.  
After recognition of the specific antigen, B and T cells strongly proliferate and 
differentiate into effector cells which clear the infection. After the elimination of the 
pathogen, numbers of effector cells strongly decline. Some of the antigen-specific 
lymphocytes differentiate into long-living memory cells which remain in a quiescent 
state for years after the antigen has been cleared. Upon reexposure to the specific 
antigen, memory cells get activated and are able to mediate a rapid and enhanced 
adaptive immune response10,11. 
1.1.3 Antigen presentation   
CD4+ and CD8+ T cells recognise their specific peptide antigens only if these are 
presented by APCs on MHC-II and MHC-I molecules, respectively. MHC-I molecules 
are expressed by all nucleated cells whereas MHC-II molecules are expressed by APCs 
of the immune system.  
MHC-I molecules present mainly endogenous peptides which are of cytosolic origin 
where proteins are degraded by the proteasome. However, in case of an infection, the 
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cell also presents pathogen-derived peptides which results in recognition and 
elimination of the infected cell by cytotoxic CD8+ T cells finally leading to the 
clearance of infection9,12.  
MHC-II molecules are expressed by professional APCs like DCs and present 
extracellular-derived antigens. For the generation of MHC-II-restricted antigens, 
extracellular antigens are internalised, degraded in lysosomes by lysosomal proteases, 
and loaded on MHC-II molecules9,13,14. Recognition of the antigen by antigen-specific 
CD4+ T cells results in activation and differentiation into T helper cells that are essential 
for full activation of macrophages, B cells, and CD8+ T cells in vivo3. In addition to this 
“classical antigen presentation”, DCs are capable of presenting extracellular antigens on 
MHC-I molecules, a process termed cross-presentation, that enables DCs to activate 
naive CD8+ T cells to become cytotoxic effector cells (cross-priming)15,16. It was shown 
that DCs are the main cell-type in vivo that is capable of cross-priming CD8+ T cells13 
which plays a role in a variety of processes, including the induction of immune 
responses against viruses that do not directly infect DCs16-19.  
In vivo, several subsets of DCs have been described that exhibit different capabilities to 
cross-present antigens probably due to differential gene expression20. Among these 
subsets, splenic CD8α+ DCs are the most efficient in cross-priming CD8+ T cells20,21. 
However, so far, intracellular compartments involved in cross-presentation are not well 
defined although there is strong evidence that phagocytosed antigen reaches the cytosol 
after internalisation and that antigen processing occurs there22,23. Recently, Burgdorf et 
al. demonstrated that the route by which antigen is taken up determines the way of 
subsequent presentation of antigen-derived peptides, i.e. whether antigen is presented 
via the classical route on MHC-II or cross-presented on MHC-I molecules24,25. In their 
study they demonstrated that the soluble model antigen ovalbumin (OVA) was 
presented on MHC-II molecules when it was taken up via pinocytosis or scavenger 
receptor-mediated endocytosis whereas OVA-derived peptides were cross-presented on 
MHC-I molecules when OVA was endocytosed via the mannose receptor (MR)24-26. 
Importantly, cross-presentation of OVA depended on the MR as MR-deficient DCs 
were not capable of cross-presenting OVA25. Following MR-mediated uptake of OVA, 
the antigen was targeted into a special type of stable early endosomal compartments 
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which did not mature into lysosomes. In these endosomal compartments OVA-derived 
peptides were loaded onto MHC-I molecules for efficient cross-presentation24. 
1.1.4 T cell activation  
The recognition of the cognate antigen presented on MHC molecules by APCs by the 
TCR of a naive T cell is a prerequisite for its activation and generally referred to as 
signal 110. However, signal 1 alone promotes T cell inactivation, e.g. by induction of 
anergy or deletion as for full activation, T cells depend on additional signals, i.e. 
costimulation via CD80 and CD86 (signal 2) as well as cytokines (signal 3) which are 
provided by the antigen-presenting APC. Delivery of these three signals results in the 
induction of a potent adaptive immune response27. In addition to indirect tolerance 
induction due to lack of signals 2 and 3, APCs are capable to induce tolerance directly 
by signalling through coinhibitory molecules like B7H1 or B7DC which bind to PD1 on 
the surface of T cells resulting in T cell inactivation28.  
Furthermore, APC-derived cytokines, i.e. signal 3, influence the differentiation of naive 
CD4+ T cells into distinct T helper (TH) cell subsets with different effector mechanisms. 
Initially two TH subsets had been described: TH1 cells, which produce interferon (IFN)-γ 
and induce strong cell-mediated immunity e.g. by activation of macrophages, and 
TH2 cells, which secrete IL-4, IL-13, and IL-25 and support B cell antibody 
production10. In addition to these classical TH cell subsets, a third subset of TH cells has 
been identified, namely TH17 cells, which are characterised by production of IL-17A, 
IL-17F, and IL-22. Although TH17 cells mediate protection against a variety of 
pathogens, they also have been linked to the development and pathology of autoimmune 
diseases such as multiple sclerosis (MS) and collagen-induced arthritis29-31. 
1.1.5 Autoimmunity 
During lymphocyte development also self-reactive lymphocytes develop which express 
receptors that recognise self antigens and could mediate immune responses against non-
harmful self-antigens. However, during their development, all B and T cell precursors 
undergo different processes of selection during which self-reactive lymphocytes are 
eliminated or inactivated, resulting in a state that is referred to as self-tolerance3. Central 
tolerance of T cells is induced in the thymus and results in depletion of the vast majority 
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of autoreactive T cells. In a first step, immature T cells undergo a positive selection 
process that ensures that only those T cells survive that recognise self-MHC molecules 
whereas T cells that cannot recognise MHC molecules die by apoptosis. This ensures 
that surviving T cells will recognise antigenic-peptides bound to MHC molecules on 
APCs in the periphery and thus be able to efficiently mount an immune response. In a 
second step, T cells that bind with high affinity to self-antigens presented on MHC 
molecules are depleted by induction of apoptosis resulting in a pool of mature non-self-
reactive CD4+ or CD8+ T cells that egress to the periphery.  
Self-reactive T cells that escape central tolerance are subject to peripheral tolerance 
induction which is mediated in several ways: Antigen recognition without adequate 
costimulation or in the presence of inhibitory signals induces clonal anergy, which is the 
incapability to respond to the antigen, and repeated recognition of the antigen in this 
context results in apoptosis. In addition, regulatory T cells (Tregs) play an essential role 
in peripheral tolerance induction as Tregs produce transforming growth factor-beta and 
IL-10 which suppresses activity of effector T cells. Deficiency in or dysfunction of 
these cells causes systemic autoimmunity, thus demonstrating the crucial importance of 
regulatory T cells for maintenance of peripheral tolerance32,33. 
Breakdown of self-tolerance results in autoimmune diseases which can be broadly 
divided into systemic autoimmune diseases, like systemic lupus erythematosus, or 
organ-specific, localised autoimmune disorders, like type I diabetes mellitus, thyroiditis, 
and MS, depending on the principal pathology of disease3,34.  
1.2 Central nervous system autoimmunity 
1.2.1 Multiple sclerosis 
MS is a chronic disease of the central nervous system (CNS) that is the leading cause of 
nontraumatic disability in young adults in the United States and Europe35. The etiology 
of MS is unknown. However, genes like certain human leukocyte antigen (HLA) 
class II alleles involved in antigen presentation to CD4+ T cells as well as environmental 
factors, e.g. viral infections or migration from low- to high-risk areas before 
adolescence, have been associated with the risk of developing disease36-39.  
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About 80 % of patients have a relapsing-remitting disease course which typically starts 
in the second or third decade of life and has a female predominance of about 2:1. The 
course of MS in an individual patient is unpredictable. However, sensory disturbances, 
limb weakness, unilateral optic neuritis, neurogenic bladder, and bowel symptoms are 
some of the typical symptoms described during onset of disease. During a relapse, 
clinical symptoms establish within several days, stabilise, and improve in response to 
corticosteroids but also spontaneously. Persistent signs of CNS dysfunction may remain 
after such a relapse and furthermore, the disease may progress between acute relapses 
which is referred to as secondary progressive MS. It is estimated that about 50 % of the 
patients will need help walking within 15 years after disease onset40.  
Up to now, IFN-β is a prominent treatment for relapsing-remitting MS although IFN-β-
based drugs are limited in their efficacy as they reduce the frequency of relapses only by 
about 30 %41. Furthermore, as IFN-β therapy is accompanied by serious side effects like 
flu-like symptoms, skin reactions, or depression, many patients terminate the therapy. 
Although the precise action of IFN-β is largely unknown, it could be demonstrated in 
mice that CNS myeloid cells are the main cell population targeted by IFN-β-
administration resulting in reduced myeloid cell activation which regulated the effector 
phase of CNS autoimmunity42.  Glatiramer acetate (GA) is a random polymer of four 
amino acids found in the MS-associated antigen myelin basic protein. Treatment with 
GA reduces the frequency of relapses in patients with relapsing-remitting MS and 
promotes the development of TH2 cells in humans43,44 It is assumed that these TH2 cells 
infiltrate the CNS during MS where they cross-react with myelin autoantigens and 
release anti-inflammatory cytokines like IL-4 or IL-1045. Novel treatment strategies 
which are currently under investigation comprise strategies that prevent 
neurodegeneration or disable a component of the immune system. One example for such 
treatment is the antibody Natalizumab, which binds to the α4β1 integrin, also known as 
very late antigen-4, expressed by activated lymphocytes and monocytes. Binding of 
Natalizumab to α4β1 results in inhibition of inflammatory cell trafficking to the CNS 
and reduces the risk of relapses by 70 % as well as the risk of sustained accumulation of 
disability46. However, despite strong efforts in pharmaceutical research, up to now no 
drug compound has been identified that completely prevents disease progression or 
stably reverses disability. 
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The neuropathology of MS in early stages is characterised by the formation of acute 
inflammatory lesions following a breakdown of the blood-brain barrier (BBB)47. Studies 
of human tissue derived from MS patients show that in early inflammatory lesions 
microglia and macrophages exhibit an activated phenotype characterised by expression 
of HLA class II. Although only few cell infiltrates are present in early inflammatory 
lesions, such infiltrates increase with time48 and are characterised by the accumulation 
of monocyte-derived and perivascular macrophages as well as the presence of T cells49. 
Several weeks after initiation, lesions are characterised by a leaky BBB, demyelinated 
areas, and the presence of cytokines and chemokines. Following remission phases, 
remyelination takes place, however it is usually incomplete48,50. 
MS is thought to be a T cell-mediated autoimmune disease and it is hypothesised that 
the initial event, which leads to the onset of MS, is the activation of autoreactive T cells 
in peripheral lymphoid tissues. CNS-derived antigens are mainly presented by APCs in 
cervical lymph nodes which are considered to be the draining lymph nodes of the brain. 
Responding T cells proliferate and migrate to the CNS where they reencounter their 
specific antigen on local APCs which are located at the perivascular space surrounding 
blood vessels of the CNS51. Local reactivation of encephalitogenic T cells results in 
induction of effector functions, such as cytokine and chemokine production, that lead to 
further recruitment and activation of additional immune cells such as inflammatory 
monocytes and B cells, thereby contributing to the perpetuation of disease52,53.     
1.2.2 Experimental autoimmune encephalomyelitis 
The animal model experimental autoimmune encephalomyelitis (EAE) has been used to 
investigate the disease of MS in rodents and some monkeys. To initiate disease, 
susceptible animals are immunised with peptide epitopes derived from myelin proteins 
in complete Freund’s adjuvant. After 1 to 2 weeks, animals develop clinical and 
neuropathologic signs characterised by cell infiltration of lymphocytes and 
macrophages which resemble the alterations observed in MS patients52. The disease 
course of EAE is divided into a T cell-mediated induction phase, which comprises the 
initial events of T cell priming and T cell-mediated initiation of disease, and the effector 
phase, which is characterised by CNS infiltration of leukocytes, establishment of local 
inflammation, and demyelination. EAE is, like MS, a T cell-mediated disease that can 
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be induced in naive animals by transfer of CD4+ T cells derived from diseased 
animals54. Among activated CD4+ T cells, cells of the TH17 lineage which express 
CCR6 have been demonstrated to be essential for the induction of disease. After entry 
of CCR6+ T cells into the CNS, more T cells, including CCR6- TH1 cells, are recruited 
to the CNS in a CCR6-independent manner55. Within the CNS, encephalitogenic T cells 
interact with myeloid cells, i.e. microglial cells and recruited inflammatory 
monocytes and macrophages, which results in local reactivation of T cells. Moreover, 
interaction also leads to reciprocal activation of myeloid cells e.g. by T cell-derived 
granulocyte macrophage colony-stimulating factor (GM-CSF)56 or IFN-γ57 or via CD40-
CD40 ligand (CD40L) interaction58,59, a process referred to as licensing of myeloid 
cells. Upon activation, macrophages and microglia produce proinflammatory cytokines 
and neurotoxic mediators which strongly contribute to perpetuation of disease60,61. 
1.2.3 Role of myeloid cells in CNS inflammation and autoimmunity  
Although autoreactive T cells are important for the initiation of EAE, many studies 
provide evidence that the main effector mechanisms leading to demyelination and CNS-
inflammation are mediated by other cell types60. Especially myeloid cells, including 
CNS-resident microglia and infiltrating inflammatory monocytes and macrophages, 
respectively, have been identified to play a crucial role in perpetuation of disease62-64 as 
they actively contribute to inflammatory processes within the CNS and disease 
pathology, i.e. demyelination and axonal damage, by production of proinflammatory 
cytokines, like TNF-α or IL-12, and neurotoxic mediators, such as NO and ROS, 
resulting in perpetuation of disease60,61. 
Microglia are CNS-resident immune cells that exhibit a ramified morphology and 
express low levels of molecules associated with macrophage function in the steady 
state65. They constantly screen the surrounding area without disturbing neuronal 
structures. However, if an injury is detected, microglia rapidly change their phenotype 
and migrate to the place of injury66. During EAE, microglial paralysis results in 
amelioration of disease demonstrating that microglia actively contribute to disease 
pathology62 and it has been shown that microglia interact with infiltrating autoreactive 
T cells by T cell-derived GM-CSF, IFN-γ, or via CD40 which results in activation of 
microglia56,57,59. Furthermore, inflammatory monocytes which are characterised by 
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expression of CCR2 and high levels of Ly-6C play a crucial role during the effector 
phase of EAE. After recruitment to the CNS, inflammatory monocytes differentiate into 
mature macrophages and upregulate inflammatory mediators like IL-12, TNF-α, or 
inducible nitric oxide synthase (iNOS)64. Ablation of inflammatory monocytes reduces 
numbers of macrophages and diminishes expression of inflammatory mediators in the 
CNS which results in amelioration of EAE63. Moreover, it has been shown that disease 
severity correlates with the absolute number of macrophages invading the CNS 
parenchyma67 and that repetitive depletion of macrophages by clodronate liposome-
treatment abrogates EAE68. Thus, myeloid cells, i.e. microglia, monocytes, and 
macrophages, play a critical role during ongoing CNS inflammation. 
1.3 Peroxisome proliferator-activated receptor gamma  
Peroxisome proliferator-activated receptor gamma (PPARγ), which belongs to the 
PPAR superfamily of nuclear hormone receptors, is involved in modulation of 
metabolism and inflammation69. PPARγ is a ligand-activated transcription factor that, 
after ligand binding, heterodimerises with the retinoid X receptor. This heterodimer 
subsequently recruits a protein complex consisting of coactivators or corepressors to 
direct transcriptional activation or repression70. PPARγ influences gene transcription by 
binding to PPAR response elements in the promoter region of target genes71 or by 
negatively interfering with proinflammatory transcription factors like nuclear factor-κΒ 
(NF-κB) which results in inhibition of gene transcription for example of 
proinflammatory cytokines72-74. Several endogenous and synthetic ligands have been 
identified for PPARγ. Endogenous ligands include unsaturated fatty acids like linoleic 
acid metabolites generated by the enzyme 12/15 lipoxygenase or 15-deoxy-12,14-
prostaglandin J2. The class of thiazolidinediones (TZDs) represents an important group 
of synthetic PPARγ ligands and one of the members, i.e. pioglitazone (PIO), was used 
in this study69,70,75,76. 
PPARγ has gained medical importance in treatment of diabetes type II as high-affinity 
ligands for PPARγ like PIO mediate improved insulin sensivity70. Due to their 
immunomodulatory effects, PPARγ agonists have also been postulated to be promising 
agents for therapeutical strategies against autoimmune diseases such as MS and 
rheumatoid arthritis77. 
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1.3.1 PPARγ  in inflammation 
PPARγ has been demonstrated to regulate DC78,79, macrophage69,73, and microglial80,81 
immunogenicity. Nencioni et al. investigated the effect of PPARγ activation on 
maturation of human monocyte-derived DCs. They demonstrated that PPARγ activation 
rendered DCs to a less stimulatory mode which was characterised by decreased 
expression of costimulatory molecules and decreased cytokine production in response to 
inflammatory stimulation78. In addition, our group could show that PPARγ is a negative 
regulator of DC maturation and function as PPARγ activation impaired inflammation-
induced upregulation of the costimulatory molecules CD40, CD80, and CD86, as well 
as IL-12 production in murine bone marrow-derived DCs (BM-DCs) resulting in 
impaired activation of naive CD4+ T cells in vitro and in vivo. Importantly, absence of 
PPARγ  in DCs resulted in enhanced CD4+ T cell activation indicating a constitutive 
regulatory function of PPARγ in DCs79.  
Several reports show that also in macrophages and monocytes PPARγ inhibits 
transcription of proinflammatory genes like iNOS or IL-6 in response to inflammatory 
stimulation in vitro72,73,82. Importantly, treatment of macrophages and monocytes with 
the TH2 cytokine IL-4 results in induction of 12/15-lipoxygenase, an enzyme that 
produces endogenous PPARγ ligands82. This indicates that the environment can directly 
influence the phenotype of macrophages by modulating PPARγ activity.  
In line with this, production of proinflammatory cytokine production upon 
inflammatory stimulation is also reduced in microglial cells by PPARγ through 
suppression of signalling molecules like myeloid differentiation primary-response gene 
8883. Furthermore, PPARγ activation in microglia inhibits also production of different 
chemokines which play an important role in attracting immune cells during ongoing 
CNS inflammation81 including chemokine ligand 2 (CCL2) that attracts inflammatory 
monocytes. 
1.3.2 PPARγ  as a pharmaceutical target to limit inflammatory diseases 
Insulin-sensitising antidiabetic TZDs are high affinity ligands for PPARγ that are in 
clinical use for treatment of type 2 diabetes. The discovery that TZDs, like PIO, 
troglitazone, or rosiglitazone perform antiinflammatory and immunomodulatory effects 
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on cells of the immune system led to the assumption that PPARγ ligands may 
effectively treat chronic inflammatory diseases beyond diabetes and indeed several 
studies have demonstrated that TZDs are effective in treatment of diseases unrelated to 
insulin resistance84. Psoriasis is a common chronic skin disease that involves epidermal 
inflammation and hyperproliferation of keratinocytes. Treatment of psoriasis patients 
with troglitazone resulted in improvement or clearance of lesions. Importantly, ligands 
for PPARγ inhibited keratinocyte proliferation and ameliorated the abnormal phenotype 
of human psoriatic skin85. Inflammatory bowel disease is a chronic inflammation of the 
gastrointestinal tract. In mice, administration of three different TZDs, i.e. PIO, 
troglitazone, and rosiglitazone, demonstrated beneficial dose-related treatment effects 
when administered prior to the onset of experimental colitis. Amelioration was 
associated with decreased levels of TNF-α and IFN-γ while levels of IL-4 and IL-10 
were increased, indicating a shift towards a more antiinflammtory TH2 response86. 
Myocarditis is an important cause of heart failure among adolescents and young adults. 
In the experimental mouse model of myocarditis, delivery of PIO resulted in 
amelioration of disease that was accompanied by inhibition of the initial expansion and 
activation of T cells as well as reduced numbers of infiltrating macrophages, CD4+ and 
CD8+ T cells in the myocardium87. Furthermore, PPARγ interfered with NF-κB 
signalling by increasing the expression of inhibitor of κB which resulted in decreased 
cytokine production88. In line with these findings, also in the animal model of MS, 
EAE, TZDs have proven to ameliorate disease when administered before or after onset 
of disease89-91. PIO-mediated amelioration of EAE was characterised by suppression of 
TH17 differentiation89 and improved neurological symptoms91. 
Hence, it has been concluded that the beneficial effects of PPARγ activation are not 
restricted to type 2 diabetes but can be extended to other chronic inflammatory diseases. 
However, the details how these agonists mediate amelioration of such diseases are 
poorly understood.  
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2 Aims of the thesis 
The nuclear transcription factor peroxisome proliferator-activated receptor gamma 
(PPARγ) is involved in the regulation of immune responses by myeloid cells, i.e. 
dendritic cells (DCs), macrophages, and microglia.  
We and others have shown that PPARγ in DCs impairs maturation in response to 
inflammatory stimulation. If PPARγ is activated, DCs exhibit reduced inflammation-
induced expression of costimulatory molecules and production of proinflammatory 
cytokines which results in CD4+ T cell anergy. However, the impact of PPARγ in DCs 
on cross-priming of CD8+ T cells is not known. Therefore, the first part of this thesis 
dealt with the following questions: 
• Does activation of PPARγ in DCs influence uptake and 
cross-presentation of soluble antigens? 
• Do PPARγ-mediated changes in cross-presentation affect 
cross-priming of naive CD8+ T cells by DCs? 
• What is the molecular mechanism that mediates PPARγ-
induced changes in cross-priming capacity of DCs? 
At least in vitro, it has been demonstrated that the immunogenicity of macrophages and 
microglia is regulated by PPARγ. As these myeloid cells play an important role in 
perpetuation of CNS inflammation during multiple sclerosis (MS) and its animal model 
experimental autoimmune encephalomyelitis (EAE), we investigated whether PPARγ 
acts as a cell-intrinsic regulator of myeloid cells during EAE: 
• Does PPARγ in myeloid cells play a protective role during 
active EAE? 
• How does PPARγ activation in myeloid cells influence the 
reciprocal interaction of myeloid cells and autoreactive 
T cells during ongoing CNS inflammation? 
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3 Materials and methods 
3.1 Materials 
3.1.1 General laboratory equipment 
Autoclave  Belimed, Köln 
AutoMACS  Miltenyi Biotec, Bergisch Gladbach 
Balances   U4100-OD2.2 and MC BA 100 (Sartorius, 
  Göttingen) 
Beakers   5 ml, 10 ml, 25 ml, 50 ml, 100 ml, 150 ml,  
 250 ml, 500 ml (Schott, Mainz) 
Centrifuges   Multifuge 3SR, Biofuge fresco, Biofuge pico 
  (Heraeus, Braunschweig) 
Counting Chamber  Neubauer (Brand, Wertheim) 
Digital camera  CCD-1300 (Vosskuehler, Osnabrück) 
ELISA Reader   SpectraMax 250 (Molecular Devices, 
  Sunnyvale, USA) 
ELISpot Reader Bioreader-2000 (Biosys, Karben) 
Erlenmeyer flasks  50 ml, 100 ml, 250 ml, 500 ml (Schott, Mainz) 
Flow cytometer  FACSCantoII (BD Biosciences, Heidelberg) 
Freezers (-20°C)  Liebherr, Biberach 
Freezers (-80°C)  Hera freeze (Heraeus, Braunschweig) 
Freezing container  Nalge Nunc Cryo (Nunc, Wiesbaden) 
Heating block  ThermoStat plus (Eppendorf, Hamburg) 
Ice machine   Icematic (Scotsman®, Frimont Bettolinc,  
 Pogliano, Italy) 
Incubators  HERAcell (Heraeus, Braunschweig) 
Magnet stirrer  IKA® Laboratory Equipment, Staufen 
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Measuring cylinders   50 ml, 100 ml, 250 ml, 500 ml, 1l (Schott 
  Mainz) 
Microscope  IX81 (Olympus, Hamburg) 
Microtiter plate washing device  Nunc-ImmunoTM Wash12 (Nalge Nunc  
 International, Thermo Fisher Scientific,   
 Wiesbaden) 
Microwave  Panasonic, Wiesbaden 
pH-meter   pH 523 (Wissenschaftlich-Technische  
 Werkstätten, Weilheim) 
Pipette-Boy  Pipetus (Hirschmann Labortechnik, Eberstadt) 
Pipettes  Gilson, Heidelberg and Eppendorf, Hamburg 
Preparation Instruments  Labotec, Göttingen 
Real-time PCR System AbiPrism 7900 HT cycler 
Refrigerators (+4°C)  Bosch, Stuttgart and Liebherr, Biberach 
Sieves, steel   University of Bonn, Department   
 “Feinmechanik” 
Sonificator  UW2070/Sonoplus (Bandeln electronic, Berlin) 
Spectrophotometers   LB 940 Multilabel Reader Mithras (Berthold 
  Technologies) 
NanoDrop™  ND 1000 (NanoDrop Products, Wilmington, 
 USA) 
Threaded bottles  100 ml, 250 ml, 500 ml, 1l, 2l (Schott, Mainz) 
Ultra-pure water system   NANOpure Diamond, Barnstead (Werner, 
  Reinstwassersysteme, Leverkusen) 
Waterbath  TW8 (Julabo, Seelbach) 
Workbench, sterile  HERAsafe (Heraeus, Hanau) 
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3.1.2 Software 
Cell^R Olympus, Hamburg 
FACS Diva V6.1.1 BD Biosciences, Germany 
FlowJo V8.8.4  Tree Star, Inc., USA 
Illustrator CS4 Adobe, USA 
Microsoft Office 2008 Microsoft, USA 
Prism 4  GraphPad Software, USA 
SPF ELISA Software Molecular Devices, USA 
Scan^R Olympus, Hamburg 
3.1.3 Consumables 
384-well plate Applied Biosystems  
4-well chamber culture dishes Nunc, Langenselbold 
BeadChip Array   MouseWG-6 v2 Expression BeadChip,  
 Illumina, USA 
Cryo vials  VWR International, Darmstadt 
Cryomolds  VWR International, Darmstadt 
ELISA plates   Microlon, 96-well, flat-bottom, high-binding 
   (Greiner Bio-one, Solingen) 
ELISpot R&D Systems, Minneapolis, USA 
FACS tubes  polystyrene, 12/75 mm (Sarstedt, Nümbrecht) 
Filtergauze (40 µm) TechFab, Geldern  
Injection needles  27G, 25G , 20G (BD Microlance, Heidelberg) 
Microtiter plates   96-well, round and flat bottom (Greiner bio-one, 
 Solingen) 
Nylon wool  Kisker GbR (by Labomedic GmbH, Bonn) 
Parafilm   Parafilm “M”® (American National Can TM, 
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 Greenwich, USA) 
Pasteur pipettes  150 mm and 230 mm (Roth, Karlsruhe) 
PD-MidiTrapTM G-25 GE Healthcare, München  
Petri dishes  10 cm (Greiner bio-one, Solingen) 
Pipette tips  10 µl, 200 µl, 1000 µl (Greiner bio-one, 
 Solingen) 
Plastic Pipettes  5 ml, 10 ml, 25 ml (Sarstedt, Nümbrecht) 
Polyamide tissue  “Gaze” (Labomedic, Bonn) 
Polypropylene tubes  sterile, 15 ml and 50 ml (Greiner bio-one, 
 Solingen) 
Reaction tubes  0.5 ml, 1.5 ml, 2 ml (Eppendorf, Hamburg) 
Scalpel  Feather (Osaka, Japan) 
Syringes   2 ml, 5 ml, 10 ml, 20 ml BD DiscarditTM (BD 
  Bioscience, Heidelberg) 
Tissue culture flasks   25 cm2, 75 cm2, or 150 cm2 (TPP, St.Louis,  
 USA or Sarstedt, Nümbrecht) 
Tissue culture plates   6-, 12-, 24-, 48-, or 96-well (TPP, St. Louis, 
 USA or Sarstedt, Nümbrecht) 
3.1.4 Chemicals and reagents  
Ammonium chloride (NH4Cl) Merck, Darmstadt 
B-27 supplement Invitrogen, Karlsruhe 
β-mercaptoethanol  Sigma Aldrich, München 
BME medium Sigma Aldrich, München 
Bovine serum albumin (BSA)  Roth, Karlsruhe 
BrefeldinA BD Biosciences, Heidelberg 
Carboxy-fluorescein diacetate  Molecular Probes, Leiden, Netherlandes  
     succinimidyl ester (CFSE)  
Carboxymethylcellulose (CMC) Sigma Aldrich, München 
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Chlorophenol red-β-galactosidase  Roche, Mannheim     
(CPRG) 
Collagenase A  Roche, Mannheim 
Complete Freund’s Adjuvant Difco Laboratories, Detroit, USA 
Cytofix/CytopermTM Fixation/ BD Biosciences, Heidelberg  
     Permeabilisation Kit 
DEPC treated water (RNase free)  Invitrogen, Karlsruhe 
Dimethylsulfoxide (DMSO)  Merck, Darmstadt 
DMEM medium  Sigma Aldrich, München 
Ethanol, absolute  Merck, Darmstadt 
Ethylene diamine tetraacetic acid  Sigma Aldrich, München  
     (EDTA) 
EDTA-Disodium (Na2EDTA) Sigma Aldrich, München 
Fetal calf serum (FCS)  PAA, Cölbe 
Fluoresbrite FITC-dyed polystyrene  Polysciences, Eppelheim    
beads (0.5 µm) 
G418 sulfate  PAA, Cölbe 
Grey’s Balanced Salt Solution  PAN Biotech, Passau    
(GBSS) 
Griess Reagent Kit Invitrogen, Kralsruhe 
H2DCFA  Molecular Probes, Leiden, Netherlands 
Heparin  Ratiopharm, Ulm 
Hoechst 33342  Molecular Probes, Leiden, Netherlands 
IMDM medium  Lonza, Köln 
Ionomycin (IONO) Sigma Aldrich, München 
Laminin  Sigma Aldrich, München 
L-Glutamine (200 mM)  PAA, Cölbe 
Liquid nitrogen  Linde, Wiesbaden 
Liposomes (clodronate or PBS) Dr. Nico van Rooijen, Amsterdam, Netherlands 
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Lymphocyte separation medium  PAA, Cölbe 
Milk powder Sigma Aldrich, München 
Monensin  BD Biosciences, Heidelberg 
Mowiol Roth, Karlsruhe 
Mycobacterium tuberculosis H37RA Difco Laboratories, Detroit, USA 
N2-supplement Invitrogen, Karlsruhe 
Natural silk 5.0  Catgut, Markneukirchen 
Neutralised streptavidin-peroxidase  Uptima, Interchim, France 
Non-essential amino acids (NEAA) PAA, Cölbe 
Normal goat serum generated in the lab 
Normal mouse serum generated in the lab 
Normal rat serum generated in the lab 
Optimem medium  Gibco, BRL, Karlsruhe 
Ovalbumin (OVA)  Serva, Heidelberg 
OvalbuminAlexa647 Invitrogen, Karlsruhe 
Paraformaldehyde (PFA) Fluca, Buchs 
Penicillin/Streptomycin (100x)  PAA, Cölbe 
Percoll Amersham Pharmacia, Freiburg 
Phosphate buffered saline (PBS)  Biochrom, Berlin 
PBS solution  Sigma Aldrich, München 
Pioglitazone tablets (30 mg) Actos, Takeda Pharmaceuticals, USA 
Pioglitazone (in vitro application) Axxora, Lörrach  
Phorbol myristate acetate (PMA) Sigma Aldrich, München 
Poly-l-ornithine Sigma Aldrich, München 
Potassium bicarbonate (KHCO3) Sigma Aldrich, München 
PowerSYBR Green PCR Mastermix Applied Biosystems, Carlsbad, USA 
RNeasy Kit Quiagen, Hilden 
RPMI 1640 medium  Sigma Aldrich, München 
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Sodium azide (NaN3) Sigma Aldrich, München 
Sulfuric acid (H2SO4), 96%  Merck, Darmstadt 
Superscript III  Invitrogen Life Technologies, Frederick, USA 
Taqman Gene Expression Mastermix Applied Biosystems, Carlsbad, USA 
TMB substrate  Uptima, Interchim, France 
TritonX Sigma Aldrich, München 
TRIzol Invitrogen Life Technologies, Frederick, USA 
Trypan blue (0.4%)  Lonza, Köln 
Trypsin/EDTA Lonza, Köln 
Tween20  Roth, Karlsruhe 
3.1.5 Buffers, media, and solutions 
3.1.5.1 Fetal calf serum (FCS) 
FCS was heat-inactivated at 56°C for 30 min and stored à 50 ml aliquots at -20°C. 
3.1.5.2 Phosphate buffered saline (PBS) 
1x PBS was adjusted to pH 7.4, aliquoted à 500 ml, autoclaved, and stored at 4°C. 
3.1.5.3 0.5 M EDTA 
186.1 g EDTA and 20 g NaOH were dissolved in 1000 ml ultra-pure water and the pH 
was adjusted to 7.8 - 8.0. The solution was autoclaved and stored at room temperature. 
3.1.5.4 5 mM β-mercaptoethanol 
178 µl of 14.3 M β-mercaptoethanol was added to 500 ml 1x PBS and kept under sterile 
conditions at 4°C. 
3.1.5.5 Ag8653 medium 
IMDM medium was supplemented with 10 % (v/v) FCS, 2 mM L-glutamine, 1 % (v/v) 
penicillin/streptomycin, 50 µM β-mercaptoethanol and kept under sterile conditions at 
4°C. 
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3.1.5.6 Bone marrow-derived dendritic cell (BM-DC) medium 
IMDM medium was supplemented with 10 % (v/v) FCS, 2mM L-glutamine, 1 % (v/v) 
penicillin/streptomycin, 50 µM β-mercaptoethanol and kept under sterile conditions at 
4°C. For BM-DC differentiation, 30 % (v/v) of Ag8653-conditioned medium containing 
granulocyte macrophage colony-stimulating factor (GM-CSF) was freshly added.  
3.1.5.7 L929 medium 
RPMI 1640 medium was supplemented with 10 % (v/v) FCS, 2 mM L-glutamine, 1 % 
(v/v) penicillin/streptomycin, 50 µM β-mercaptoethanol and kept under sterile 
conditions at 4°C. 
3.1.5.8 Bone marrow-derived macrophage (BM-M) and T cell culture medium 
RPMI 1640 medium was supplemented with 10 % (v/v) FCS, 2 mM L-glutamine, 1 % 
(v/v) penicillin/streptomycin, 50 µM β-mercaptoethanol and kept under sterile 
conditions at 4°C. For BM-M differentiation, 30 % (v/v) L929-conditioned medium 
containing macrophage colony-stimulating factor (M-CSF) was freshly added.  
3.1.5.9 Primary microglia medium 
DMEM medium was supplemented with 10 % (v/v) FCS, 2 mM L-glutamine, 1 % (v/v) 
penicillin/streptomycin, 50 µM β-mercaptoethanol, and 1 % (v/v) NEAA and kept 
under sterile conditions at 4°C. 
3.1.5.10 Neuronal medium 
BME-based neuronal medium was supplemented with 2 % B-27 supplement, 1 % 
glucose, and 1 % FCS and kept under sterile conditions at 4°C. 
3.1.5.11 FACS buffer 
1x PBS containing 1 % (v/v) FCS and 0.1% (v/v) NaN3. Stored at 4°C. 
3.1.5.12 MACS buffer 
1x PBS containing 1 % (v/v) FCS and 2 mM EDTA. Stored under sterile conditions at 
4°C. 
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3.1.5.13 ACK lysis buffer 
16.58 g NH4Cl, 2 g KHCO3, 74.4 mg Na2EDTA was dissolved in 2000 ml ultra-pure 
water and the pH was adjusted to 7.2 - 7.4. Stored under sterile conditions at room 
temperature. 
3.1.5.14 ELISA coating buffer 
0.1 M NaHCO3 in ultra-pure water, the pH was adjusted to 8.2, autoclaved, and stored at 
4°C. 
3.1.5.15 ELISA blocking buffer 
1 % BSA (w/v) in 1x PBS, prepared freshly. 
3.1.5.16 0.18 M H2SO4 TMB stopping solution 
5 ml 96 % H2SO4 was added to 500 ml ultra-pure water and kept at room temperature. 
3.1.5.17 ELISA washing buffer 
1x PBS containing 0.01 % (v/v) Tween20. 
3.1.5.18 4% (w/v) PFA solution 
8 g PFA was dissolved in 200 ml 1x PBS by gradual heating. The pH was adjusted to 
7.4. Stored at room temperature.  
3.1.5.19 Permeabilisation buffer 
1 x PBS containing 0.5 % (w/v) BSA + 0.25 % Triton X. 
3.1.5.20 Blocking solution I 
1x PBS containing 50 mg/ml milk powder, 1 % normal mouse serum, 1 % normal rat 
serum, and 1 % monoclonal antibody 2.4G2. The solution was freshly prepared and 
used for microscopical analysis of S8L presentation (3.2.13.1). 
3.1.5.21 Blocking solution II 
1x PBS containing 5 % BSA, 0.5 % normal goat serum, and 0.125 % TritonX used for 
immunohistochemical staining of neuron-microglial cocultures (3.2.13.2). 
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3.1.5.22 Percoll solutions 
30 %, 37 %, and 70 % Percoll solutions were freshly prepared by diluting 100 % Percoll 
solution with PBS to the required concentration. 
3.1.5.23 Chlorophenol red-β-galactoside (CPRG) solution 
250 ml DMEM medium and 250 ml GBSS were mixed and supplemented with 5 % 
(v/v) FCS, 2mM L-glutamine, 1 % (v/v) penicillin/streptomycin, 50 µM β-
mercaptoethanol, and 0.2 mM CPRG. The solution was kept under sterile conditions at 
4°C. 
3.1.6 Primers for quantitative real-time RT-PCR  
  FW RV 
IFN-γ  5´-GAACTGGCAAAAGGATGGTGA-3´ 5´-TGTGGGTTGTTGACCTCAAAC-3´ 
IL-1β  5´-GCCCATCCTCTGTGACTCAT-3´ 5´-AGGCCACAGGTATTTTGTCG-3´ 
IL-12p40 5´-CCTGAAGTGTGAAGCACCAA-3´ 5´-TCAGGGGAACTGCTACTGCT-3´ 
IL-23p19 5´-GACTCAGCCASCTCCTCCAG-3´ 5´-GGCACTAAGGGCTCAGTCAG-3´ 
TNF-α  5´-CATCTTCTCAAAATTCGAGTGACAA-3´ 5´-TGGGAGTAGACAAGGTACAACCC-3´ 
3.1.7 Peptides 
Peptide   Company  Application   
MOG35-55    Biotrend   in vivo  
MOG35-55    Pineda   in vitro  
OVA257-264 (SIINFEKL/S8L) Pineda   in vitro   
3.1.8 Recombinant cytokines and chemokines 
For long-term storage, recombinant cytokines and chemokines for ELISA standard were 
kept at -80°C. Working aliquots were stored at -20°C.  
Cytokine / chemokine  Company   
IL-2   eBioscience, USA  
IL-6   eBioscience, USA 
IFN-γ    eBioscience, USA 
TNF-α   eBioscience, USA 
CCL2    eBioscience, USA 
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3.1.9 Antibodies  
3.1.9.1 Antibodies for flow cytometric analysis 
Fluorochrome-labelled antibodies for flow cytometric analysis of expression of diverse 
surface antigens and for intracellular cytokine staining were obtained from eBioscience 
or BD Pharmingen except for the mannose receptor (MR) which was ordered from AbD 
serotec. All antibodies were used in previously titrated concentrations.  
Antigen  Isotype   Clone    
B7DC   rat IgG2a,κ   TY25    
B7H1   rat IgG2a,λ   M1H5   
CD4   rat IgG2b,κ   GK1.5   
CD8α   rat IgG2b,κ   53-6.7 
CD11b  rat IgG2b,κ   M1/70   
CD11c   hamster IgG   N418   
CD115  rat IgG2a,κ   AFS98 
CD16/32  rat IgG2b,κ   2.4G2 
CD40   rat IgG2a,κ   1C10   
CD45   rat IgG2b,κ   30-F11  
CD45.1  mouse IgG2a,κ  A20  
CD45.2  mouse IgG2a,κ  104 
CD80   hamster IgG   16-10A1  
CD86   rat IgG2b,κ   P03.1 
ICOSL  rat IgG2a,κ   HK5.3  
I-Ab    mouse IgG2a,κ  AF6-120.1    
IFN-γ   rat IgG1,κ   XMG1.2 
IL-6   rat IgG1,κ   MP5-20F3 
IL-17A  rat IgG2a,κ   eBio17B7 
Ly-6C   rat IgG2c   HK1.4 
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Ly-6G   rat IgG2a,κ   1A8 
MR   rat IgG2a,κ   MR5D3 
TNF-α   rat IgG1,κ   MP6-XT22 
3.1.9.2 Antibodies for ELISA 
All antibodies used in cytokine and chemokine ELISAs were purchased from 
eBioscience as matching antibody pairs which included a primary unlabelled capture 
antibody and a biotinylated detection antibody and each antibody was applied in 
previously titrated amounts. For detection of CCL2, the antibodies were ordered as 
ELISA Ready-Set-Go!® and antibodies were used according to the manufacturer’s 
instructions. 
Cytokine  Clone capture antibody Clone detection antibody 
IFN-γ   AN-18    RA-6A2 
IL-2   JES6-1A12   JES6-5H4 
IL-6   MP5-20F3   MP5-32C11 
TNF-α   TN3-19.12   Polyclonal 
CCL2   4E2    2H5 
3.1.9.3 Antibodies for in vitro activation of T cells 
Antigen  Clone    Source    
 CD3   145.C11   generated in the lab 
CD28   37.52    eBisociences 
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3.1.9.4 Antibodies for immunohistochemical staining 
Antigen Clone Source  
S8L complexed to H-2Kb 25D1.16  R. Germain + J. Yewdell 
β-tubulin 3   polyclonal mouse Sigma Aldrich, München 
 Goat-anti-mouse polyclonal goat Jackson Immuno Research, 
   Suffolk, UK 
Iba1    polyclonal rabbit Wako Chemicals, Neuss 
Goat-anti-rabbit  polyclonal goat Invitrogen, Karlsruhe 
amyloid precursor protein polyclonal goat Chemicon, Temecula, USA 
(APP) 
CD3     CD3-12  Serotec, Düsseldorf 
MAC-3    M3/84   BD Biosciences, Heidelberg  
3.1.9.5 Antibodies coupled to magnetic beads (“MACS Beads”) 
Murine αCD4, αCD11b,  αCD11c, αCD90.2, and αbiotin antibodies conjugated to 
magnetic beads as well as CD8+ T cell isolation kit were obtained from Miltenyi 
Biotech, Bergisch Gladbach, Germany. 
3.1.9.6 PD1 blocking antibody for in vitro application 
To block interaction of B7H1 with PD1 in cocultures of BM-DCs and OT-I T cells,     
20 µg/ml antibody against PD1 (clone J43)92 or the isotype control was added (Hamster 
IgG).  
3.1.9.7 Antibody for in vivo depletion of CCR2+ inflammatory monocytes 
The αCCR2 antibody MC-21 was a kind gift from Prof. Dr. M. Mack (University of 
Regensburg, Germany). Rat IgG2b (BD Bioscience) served as Isotype control antibody.  
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3.1.10 Inhibitors 
Inhibitor Company   
Monensin eBioscience, USA 
BrefeldinA eBioscience, USA 
3.1.11 Virus 
Virus  Description    Source    
AdOVA  E1- and E3-deleted recombinant Dr. Andreas Untergasser;
 adenoviral vector expressing  Prof. Dr. Ulrike Protzer     
the full length OVA protein        
under the CMV promoter 
3.1.12 Cell lines 
3.1.12.1 Ag8653 
Ag8653 is a hybridoma cell line that is used to produce GM-CSF-containing 
supernatant which was used for the generation of bone marrow-derived dendritic 
cells93,94 (3.2.1.2). 
3.1.12.2 L929 
L929 is a hybridoma cell line that is used to produce M-CSF-containing supernatant 
which was used for the generation of bone marrow-derived macrophages95 (3.2.1.5). 
3.1.12.3 B3Z 
B3Z is a CD8+ T cell hybridoma that recognises the OVA-derived peptide SIINFEKL 
(S8L) in the context of H-2Kb molecules96. Following activation of the T cell, the β-
galactosidase gene is expressed under the control of the IL-2 promotor and activation 
can be assessed by measuring the conversion of the chromogenic substrate CPRG by 
absorbance spectrophotometry at 595 nm. 
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3.1.12.4 RMA 
Lymphoblast cell line derived from C57BL/6N mice obtained from LGC Standards 
GmbH, Wesel.  
3.1.13 Mouse strains 
All mice were bred under pathogen free conditions in accordance with the institutional 
guidelines of the local animal facility House of Experimental Therapy at the University 
of Bonn. For all experiments, mice between 6 and 18 weeks of age were used. 
Strain Source  Description     
C57BL/6  Charles River   wild type strain (H-2Kb)   
MR-/- Dr. Michel Nussenzweig mice that lack the mannose receptor 
  (MR)97 
OT-I Rag-1-/- Dr. William R. Heath TCR transgenic line which produces  
 MHC-I-restricted, OVA-specific  
  CD8+ T cells; mice lack mature T and  
  B cells due to deficiency in 
  recombination-activating gene 1 
  (Rag-1)98 
B7H1-/- Dr. Lieping Chen mice lack the coinhibitory molecule  
    B7H199 
PPARγfl/fl Charles River  mice carry two loxP sites flanking 
exons two and three of the PPARγ 
gene100 
CD45.1 Charles River mice that carry the congenic marker 
CD45.1 
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LysM-Cre x PPARγfl/fl own breeding mice expressing the Cre-recombinase 
under the control of the lysozyme M 
(LysM) promoter101 crossed to 
PPARγfl/fl mice; mice lack PPARγ 
specifically in myeloid cells 
(Figure 9a) 
2D2 own breeding TCR transgenic line which produces 
MHC-II-restricted, MOG35-55-specific 
CD4+ T cells102  
Thy1.1 (CD90.1) Charles River / own mice that express the congenic 
breeding marker Thy1.1 (or CD90.1) 
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3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 Production of GM-CSF-containing supernatant 
Ag8653 fibroblasts were taken up in Ag8653 medium and cultured in 30 ml in 175 cm2 
flasks until confluency at 37°C. The addition of the antibiotic Neomycin (G418; 
1 mg/ml) allowed to positively select transgenic modified cells that bear the capacity to 
produce GM-CSF. After confluency was reestablished, cells were harvested, washed 
three times with PBS, and 1.5x106 cells, resuspended in 30 ml Ag8653 medium without 
G148, were transferred to a new 175 cm2 flask. After three days, the supernatant was 
collected and centrifuged for 10 min at 553 × g to remove remaining cells. Following 
another centrifugation step (15 min, 1942 × g) of the supernatant in order to remove 
debris, the supernatant was collected, sterile filtered (pore size = 0.2 µm), and stored in 
aliquots at -20°C. 
3.2.1.2 Generation of BM-DCs 
The hind legs of wild type C57BL/6 mice were dissected and collected in PBS on ice. 
After removal of skin residues and muscle tissue, bones were disinfected with 70 % 
Ethanol, and subsequently washed in PBS. Femoral and tibial bones were opened on 
each side and the bone marrow was flushed out with medium using a syringe attached to 
a 27 G needle. Following a centrifugation step of 5 min at 486 × g, cells were filtered 
through a 30 µm cell strainer, and centrifuged again at 486 × g for 10 min. Cells were 
resuspended in BM-DC culture medium supplemented with freshly added 30 % 
GM-CSF-containing Ag8653 supernatant. Cells were plated on 3 petri dishes per 2 hind 
legs in 15 ml per dish and incubated at 37°C. At day 3 or 4, cells were split 1:1 into new 
petridishes. BM-DCs were used for experiments after seven or eight days of cultivation. 
For PIO-treatment, 10 µM PIO was added to the bone marrow cell culture from day 0 of 
differentiation procedure. When medium was changed, 10 µM PIO was freshly added to 
the appropriate petridishes. 
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3.2.1.3 Conditional knockout of PPARγ  in BM-DCs 
Conditional PPARγ knockout BM-DCs were generated in vitro by Cre-mediated site-
specific recombination of loxP sites integrated into exon 1 and exon 2 of the PPARγ 
gene of PPARγfl/fl mice. First, bone marrow precursor cells were isolated as described in 
3.2.1.2 from PPARγfl/fl or, as control, wildtype C57BL/6 mice. Precursor cells were 
treated with 3 µM of a membrane-permeable Cre recombinase (HTNCre) for 6 h, 
washed twice, and cultured as described in 3.2.1.2 for 4 days. On day 3 of the 
differentiation period, the protocol was repeated and cells were cultured for another 4 
days. PIO-treatment was performed by addition of 10 µM PIO during the whole 
differentiation period. 
3.2.1.4 Generation of M-CSF containing supernatant 
L929 cells were taken up in L929 medium and cultured in 30 ml in 175 cm2 flasks for 
48 h at 37°C. Then, L929 cells were split and 0.5x105/ ml seeded onto 15 cm2 dishes. 
After four days, the supernatant was collected and centrifuged for 10 min at 553 × g to 
remove remaining cells. Afterwards, the supernatant was sterile filtered (pore size = 
0.2 µm), and stored in aliquots à 45 ml at -20°C. 
3.2.1.5 Generation of BM-Ms 
Generation of BM-Ms was performed as described for BM-DCs (3.2.1.2). To generate 
BM-Ms, 30 % M-CSF-containing L929 supernatant was freshly added to the culture. At 
day 3 or 4, the supernatant containing non-adherent cells was sucked off and fresh 
medium with 30 % M-CSF-containing supernatant was added. BM-Ms were used for 
experiments after seven days of cultivation.  
For PIO-treatment, 10 µM PIO was added to the bone marrow cell culture from day 0 of 
the differentiation procedure. When medium was changed, 10 µM PIO was freshly 
added to the appropriate petridishes. 
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3.2.1.6 Generation of primary microglia 
To prepare mixed glial cultures, brains were removed from post-natal day 1–5 C57BL/6 
mice. Brains were first stripped of the meninges and cortices and afterwards 
mechanically dissociated. Cell homogenates were seeded into 75 cm2 culture flasks in 
10 ml primary microglia medium which was changed when it became acidic. After 2 
weeks, microglial cells had started to grow on the established stromal cell layer . From 
this time, microglial cells were harvested by vigorously tapping the flasks and filtering 
the cell suspension through 40 µm wide gauze to remove stroma cells that had been 
shaked of. Fresh medium was added and microglia were again harvested, when 
microglia cells had differentiated again.   
For PIO-treatment, 10 µM PIO in 10 ml fresh medium was added to the flasks. After 
4 days half the medium was changed and 5 ml of fresh medium containing 10 µM PIO 
was added. Untreated cells were treated the same way without addition of PIO. 
3.2.1.7 Generation of primary neurons 
4-well chamber culture dishes were pretreated for 24 h with 0.01 mg/ml poly-l-ornithine 
and 10 µg/ml laminin. To establish primary neuronal cultures, brains were prepared 
from C57BL/6 mice embryos (E15-E16) and collected in PBS on ice. Then, hippocampi 
were isolated and dispersed mechanically. After centrifugation, cells were resuspended, 
counted, and seeded at a concentration of 1x105 cells/ml in BME-based neuronal 
medium with 1 ml per well. After 4 d, neurons had become morphologically mature and 
were cocultured with primary microglial cells as described in 3.2.12.7. 
3.2.2 Flow-cytometry 
Cells were stained as described in the following sections. For all experiments, data was 
acquired using a FACSCantoII and results were analysed using FlowJo software. 
3.2.2.1 Surface staining 
Staining for surface molecules was performed in 96-well round bottom plates with 
1x105-1x106 cells per well. Cells were washed once with FACS buffer, before addition 
of 50 µl of the appropriate antibody + anti-CD16/32 (to block the FcγR) diluted in 
FACS-buffer at a previously titrated concentration. Staining was performed for 10 min 
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at room temperature. Then, cells were washed once with FACS buffer and analysed by 
flow-cytometry.  
For surface analysis of blood cells, erythrocytes were lysed before staining procedure. 
To this end, blood was collected in PBS containing heparin and centrifuged for 3 min at 
3000 rpm in Biofuge Fresco (Heraeus). After the supernatant was discarded, 500 µl 
ACK lysis buffer was added, and samples were incubated for 10 min at room 
temperature. After 3 min centrifugation at 3000 rpm in a Biofuge Fresco (Heraeus), 
cells were resuspended in FACS buffer and stained for surface molecules. 
3.2.2.2 Intracellular staining of the mannose receptor (MR) 
For intracellular staining of the MR in BM-DCs, cells were surface stained for CD11c 
(3.2.2.1), fixed in 4 % PFA for 15 min on ice, permeabilised with permeabilisation 
buffer, and stained with an antibody against the MR diluted in permeabilisation buffer. 
Staining was performed for 30 min on ice. After washing with permeabilisation buffer, 
cells were resuspended in FACS buffer, and analysed by flow-cytometry.  
3.2.2.3 Intracellular cytokine staining 
For intracellular cytokine staining, cells were cultured for 4 h in the presence of 1 µl/ml 
of both, Monensin and BrefeldinA, and staining was performed using the BD 
Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit according to the 
manufacturer´s protocol. Briefly, after staining of surface molecules, cells were fixed in 
BD Cytofix/Cytoperm solution for 15 min on ice, followed by two wash steps with BD 
Perm/Wash buffer. The antibody was added in BD Perm/Wash buffer and staining was 
performed for 30 min on ice, followed by another two wash steps with BD Perm/Wash 
buffer. For flow cytometric analysis, cells were resuspended in FACS Buffer.  
3.2.2.4 Uptake of soluble OVA – in vitro 
To detect uptake of soluble OVA, 3 µg/ml soluble Alexa647-labelled OVA was added 
to BM-DCs. After incubation for 15 min at 37°C, BM-DCs were collected in FACS 
buffer, stained for surface expression of CD11c (3.2.2.1), washed, and analysed by 
flow-cytometry. 
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3.2.3 Detection of reactive oxygen species (ROS) 
To determine the production of ROS by BM-Ms or pMg, BM-Ms were prestimulated 
with 100 ng/ml LPS for 30 min and pMg were prestimulated with 1 µg/ml LPS for 24 h.  
After the stimulation period, cells were washed three times with 37°C warm PBS and 
20 µM H2DCFDA in 37°C warm PBS was added to the cells. ROS-mediated 
convergence of H2DCFA into fluorescent DCF was detected in a fluorescence plate 
reader at a wavelength of 485 nm (excitation) and 530 nm (emission). 
3.2.4 Detection of nitric oxide (NO) 
To determine NO production by BM-Ms or pMg, cells were stimulated for 48 h with 
100 ng/ml LPS or 1 µg/ml LPS + 5 pg/ml IFN-γ, respectively. Nitrite concentrations 
were determined in the supernatants with the Griess Reagent Kit for Nitrite 
Determination. A standard dilution of nitrite standard solution (component C) in 
deionised H2O was prepared, starting from 100 µM with dilution steps of 1:1. For 
analysis, 150 µl of the standard or supernatants were mixed with 130 µl deionised H2O 
+ 10 µl component A + 10 µl component B. The mixture was incubated for 30 min at 
room temperature. Afterwards, the concentration of nitrite was measured at a 
wavelength of 548 nm in a spectophotometric microplate reader. 
3.2.5 Quantitative real-time RT-PCR 
For quantitative real-time RT-PCR, mRNA was isolated from the upper cervical myelon 
of EAE-diseased mice (on day 21 of EAE) or from in vitro stimulated BM-Ms or pMg 
using the RNeasy kit from Quiagen according to the manufacturer’s protocol. To 
determine mRNA levels of inflammatory cytokines, chemokines, and iNOS we 
performed reverse transcription and amplified cDNA. The PCR reaction mixture was 
prepared with PowerSYBR Green PCR Master Mix or TaqMan Gene Expression 
Master Mix. For analysis, we used gene-specific primers (IL-1β, IL-12p40, IL-23p19, 
TNF-α, IFN-γ), QuantiTect Primer Assays (iNOS) from Qiagen, or FAM-labelled 
TaqMan probes (CCL2, CCL3, CCL5, CCL20, CXCL10, GAPDH). Data was analysed 
by the ΔCT method and normalised to GAPDH expression. 
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3.2.6 Enzyme-linked immunosorbent assay (ELISA) 
ELISA microtiter plates were coated with 50 µl per well of the primary capture 
antibody in ELISA coating buffer and incubated for 1 h at 37°C or overnight at 4°C. 
After removing unbound antibody by three wash steps with ELISA washing buffer, 
100 µl ELISA blocking buffer was added to the wells for 30 min at room temperature, 
which was removed by another three wash steps. After upside down centrifugation of 
the plate for 2 min at 550 × g, 50 µl of each sample (supernatants in triplicates) as well 
as the cytokine standard (1:4 dilution series, 9 steps) was added and plates were 
incubated for 1 h at 37°C or overnight at 4°C. After the plate was washed three times, 
50 µl of the biotinylated detection antibody in blocking buffer was added, and the plate 
was incubated for 1 h at 37°C or overnight at 4°C. After thorough washing with ELISA 
washing buffer, 1 µg/ml streptavidin-conjugated peroxidase in PBS was added for 30 
min, incubated at 4°C, subsequently washed, and centrifuged upside down for 2 min at 
550 × g. 50 µl of TMB substrate was applied to each well and the absorbance was 
measured at 650 nm in an ELISA plate reader. The enzymatic reaction was stopped by 
addition of 50 µl 0.18 M H2SO4 stopping solution. The absorbance was measured at 
450 nm again.   
3.2.7 Enzyme-linked immunosorbent spot (ELISpot) assay 
ELISpot analysis was performed according to the manufacturer’s instructions. To this 
end, required wells of the IFN-γ or IL-17A microplates were incubated with 200 µl of 
sterile culture medium for 20 min at room temperature. The culture medium was 
aspirated and 1x104 cells isolated from the CNS were added in 50 µl to each well. Next, 
2x104 DCs which had been loaded with 10 µM MOG or left untreated were added in 
50 µl to the appropriate wells. The cells were incubated at 37°C for 24 h. Afterwards the 
plates were washed by filling each well with ELISpot wash buffer from the R&D 
Systems Kit using a squirt bottle. After the last wash step, any washing buffer was 
completely removed by aspiration. Then, 100 µl of the detection antibody was added 
and the plate was incubated overnight at 4°C. After thorough washing and aspiration of 
the washing buffer, 100 µl of Strepatavidin-conjugated alkaline phosphatase was added 
and incubated for 2 h at room temperature. Next, after plates were washed thoroughly, 
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100 µl BCIP/NBT Chromogen was added to each well and incubated for 1 h at room 
temperature. Subsequently, wells were rinsed with deionised water to remove residual 
BCIP/NBT Chromogen. Last, the flexible plastic underdrain was removed from the 
bottom of the microplate and the bottom of the microplate was wiped, dried completely 
at room temperature, and spot numbers were counted with an automated ELISpot 
Reader. 
3.2.8 Oral treatment with pioglitazone (PIO) 
Seven days before splenic DC isolation or MOG35-55 immunisation as well as during 
EAE, mice were treated with 30 mg/kg body weight PIO dissolved in 0.5 % 
carboxymethylcellulose (CMC) or the vehicle only by daily oral gavage.  
3.2.8.1 OVA uptake in vivo 
On day 7 of oral PIO-treatment, mice were injected intravenously (i.v.) with 5 µg/g 
body weight fluorescently-labelled OVAAlexa647 in PBS for analysis of MR expression 
and OVA uptake. After 45 min, splenic DCs were isolated as described in 3.2.10, 
stained for CD11c (see 3.2.2.1) and the MR (see 3.2.2.2), and analysed by flow-
cytometry.  
For coculture assays of splenic DCs ex vivo with B3Z cells, mice received 100 µg/g 
body weight purified OVA in PBS i.v. After 45 min, splenic DCs were isolated and 
coculture assays were set up as described in 3.2.12.5.  
3.2.9 Determination of cell numbers 
To determine the cell number of a cell suspension, an aliquot was diluted in 0.04% 
trypan blue to allow discrimination of live and dead cells. 10 µl of this suspension was 
applied to a Neubauer counting chamber and living cells were counted in all four large 
squares. The cell count was calculated using the following formula:  
cell number / ml = (counted viable cells / 4) x dilution x 104. 
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3.2.10 Isolation of splenic dendritic cells  
Spleens were removed and digested by perfusion with 0.4 mg / ml CollagenaseA in 
PBS. After incubation in a water bath for 15 min at 37°C, spleens were homogenised by 
gently pressing the tissue through a metal cell strainer, and cell homogenates were 
resuspended in ice cold MACS buffer. Cells were centrifuged for 5 min at 486 × g and 
the supernatant was discarded. Cells were resuspended in MACS buffer, filtered 
through 40 µm gauze, and centrifuged for 5 min at 486 × g. The cell pellet was 
resuspended in 500 µl of MACS Buffer containing 20 µl of αCD11c micro beads per 
spleen and the sample was incubated for 15 min at 4°C. Afterwards, 25 ml MACS-
buffer was added and cells were centrifuged for 5 min at 486 × g in order to remove 
unbound magnetic beads. Cells were resuspended in 3 ml MACS buffer and purified by 
positive selection using the AutoMACS Separation Technology. After the isolation 
procedure, DCs were washed once, counted, and cell numbers were adjusted to the 
required concentration. 
3.2.11 Isolation of splenic naive CD4+ and CD8+ T cells  
For the isolation of naive CD4+ T cells spleens and inguinal as well as mesenteric 
lymph nodes were homogenised by gently pressing the tissue through a metal cell 
strainer. After centrifugation for 5 min at 486 × g, cells were resuspended in MACS 
buffer, filtered through 40 µm wide gauze, and again centrifuged for 5 min at 486 × g. 
Afterwards, cells were resuspended in 500 µl of MACS Buffer and 25 µl of αCD4 
microbeads were added per spleen and lymph nodes. Cells were incubated for 15 min at 
4°C and the reaction was stopped by adding a large volume of MACS buffer. Cells were 
centrifuged for 5 min at 486 × g, resuspended in 3 ml MACS buffer, and purified by 
positive selection using the AutoMACS Separation Technology.   
For isolation of naive CD8+ T cells from OT-I Rag-1-/- mice, spleens and lymph nodes 
were collected in PBS on ice. After homogenisation of the tissue by gently pressing it 
through a metal cell strainer, the cell suspension was collected, and centrifuged for 5 
min at 486 × g. After resuspension in 10 ml 37°C warm T cell medium, cells were 
applied to a sterile 10 ml syringe filled with 0.6 g nylon wool, which had been blocked 
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for 1 h with T cell medium, and were incubated for 1 h at 37°C to allow macrophages 
and DCs to adhere. Next, T cells were collected by carefully rinsing the nylon wool 
with 20 ml T cell medium (37°C). 
After the isolation procedure, T cells were washed once with T cell medium, counted, 
and cell numbers were adjusted to the required concentration.  
3.2.12 Coculture assays  
3.2.12.1 Coculture of BM-DCs with B3Z or OT-I T cells 
For determination of cytokine production / CPRG conversion and proliferation assays, 
BM-DCs or freshly isolated splenic DCs were cocultured with T cells at a ratio of 1:2 
(DC : T cell), if not otherwise stated. In most experiments, 0.5 mg/ml purified OVA was 
added to cocultures. Supernatants were collected after 48 h of coculture and cytokines 
were detected by ELISA (3.2.6). To determine cytokine production after restimulation, 
viable CD8+ T cells were harvested on day 5 of coculture by density gradient 
centrifugation with lymphocyte separation medium, washed twice, and cultured in 
triplicates for another 24 h in the presence of 10 µg/ml αCD3 antibody coated on a 96-
well flatbottom plate. Cytokine production was determined after 24 h by ELISA (3.2.6). 
3.2.12.2 Proliferation Assays 
To determine proliferation profiles, OT-I T cells were labelled with 2.5 µM CFSE in 
5 ml PBS for 10 min at 37°C after isolation as desribed in 3.2.11. The CFSE reaction 
was stopped by addition of 5 ml FCS for 1 min at room temperature followed by 
centrifugation for 5 min at 486 × g. Then, cells were resuspended in medium, counted, 
and cell numbers were adjusted to the required cell concentration. Proliferation was 
analysed by flow-cytometry after 3 days of coculture. 
3.2.12.3 In vitro cytotoxicity assay 
RMA cells were resuspended and divided into two fractions of which one fraction was 
loaded with 1 µM of the H-2Kb peptide S8L for 15 min at 37°C. Subsequently, peptide-
loaded cells were labelled with 2.5 µM CFSE whereas the unloaded cell fraction was 
labelled with 0.25 µM CFSE for 15 min at 37°C. Cells were washed once with cold 
PBS, resuspended, and mixed in a 1:1 ratio. 5x103 cells, i.e. 2.5x103 S8L-loaded cells, 
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were seeded into 96-well plates. OT-I T cells, that were isolated from cocultures with 
PIO-treated or untreated BM-DCs by employing a gradient with lymphocyte-separation 
medium, were added to the target cells in different target : T cell ratios. After 4 h, cells 
were analysed by flow-cytometry and the specific cytotoxicity was calculated as 
follows: 
% OVA-specific cytotoxicity =  
100 - [100 x (CFSEhigh / CFSElow)sample / (CFSEhigh / CFSElow)control] 
5x103 RMA cells cultured without T cells served as controls. 
3.2.12.4 In vivo cytotoxicity assay 
PIO-treated or vehicle-treated wild-type mice were immunised with 1x106 PIO-treated 
or untreated OVA-loaded BM-DCs subcutaneously (s.c.). 5 d later, target cells were 
prepared to assess in vivo cytotoxic activity. As target cells, splenocytes were either 
pulsed with S8L peptide (1 µg/ml, 45 min at 37 °C) and labelled with a high 
concentration of CFSE (1 µM, 15 min at 37 °C; CFSEhigh cells) or mock-treated and 
labelled with a low concentration of CFSE (0.1 µM; CFSElow cells). Cells were washed 
twice with PBS and equal numbers of cells from each population were injected i.v. (107 
target cells). Animals were sacrificed after 18 h and the presence of target cells in the 
draining lymphnodes was determined by flow-cytometry. The specific cytotoxicity was 
calculated as in 3.2.12.3. Target cells injected into non-immunised mice served as 
controls. 
3.2.12.5 OVA uptake in vivo and ex vivo coculture of splenic DCs with B3Z cells 
45 min after injection of purified OVA (see 3.2.8.1), splenic DCs were isolated as 
described in 3.2.11 and 0.5x105 DCs were cocultured with 1x105 B3Z cells in 96-well 
plates for 72 h. Activation of B3Z cells was determined by measuring the conversion of 
CPRG by absorbance spectrophotometry at 595 nm. 
3.2.12.6 Coculture of memory T cells with BM-DCs 
For induction of an OVA-specific CD8+ T cell memory response in vivo, CD8+ T cells 
derived from OT-I mice carrying the congenic marker CD90.2 were transferred i.v. into 
C57BL/6 mice carrying the congenic marker CD90.1. After 24 h, mice were immunised 
with OVA-expressing adenoviruses (AdOVA, 1.107 PFU / mouse) i.v.. After 30 days, 
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OVA-specific CD8+ T cells were isolated by immuno-magnetic separation using a 
CD8+ T cell isolation kit according to the manufacturer’s instructions followed by 
further purification using magnetic beads labelled with an antibody directed against 
CD90.2. Isolated CD8+CD90.2+ T cells were restimulated in vitro by either PIO-treated 
or untreated OVA-loaded BM-DCs. After 36 h, production of IFNγ was assessed by 
ELISA (3.2.6). 
3.2.12.7 Coculture of primary microglia with primary neurons 
pMg that were pretreated with 10 µM PIO for 5 days or left untreated were harvested 
and stimulated for 48h with 1 µg/ml LPS + 10 ng/ml IFN-γ with or without PIO in 
primary microglia medium which contained N2-supplement instead of FCS. Microglia 
were harvested, resuspended in neuronal medium, and 5x104 pMg were added to each 
well of neuron culture chamber slides containing 2.5x104 neurons (ratio of 1:5 
(microglia : neurons)). After 24 h, staining and microscopy was performed as described 
in 3.2.13.2. 
3.2.13 Microscopy 
3.2.13.1 Microscopical analysis of S8L presentation by BM-DCs 
BM-DCs were treated with 10 µM PIO or left untreated as described in 3.2.1.2. On day 
6 of differentiation procedure, 10 mg/ml purified OVA was added to the appropriate 
cell culture dishes overnight. Then, 4x105 BM-DCs were seeded into 24-well plates and 
left at 37°C to allow cells to adhere. Next, cells were washed with PBS and incubated 
with 300 µl blocking solution I to block non-specific binding sites. After incubation for 
1 h at room temperature, cells were washed three times with PBS, and stained with the 
biotinylated antibody 25D1.16 (1:50 in PBS + 1 % normal mouse serum) to detect the 
OVA-derived peptide SIINFEKL (S8L) bound to H-2Kb molecules. Following 30 min 
of incubation at room temperature, cells were washed three times, incubated with 
Alexa647-conjugated strepatavidin for 15 min at room temperature, and washed three 
times with PBS. Lastly, 1.2 µg/ml Hoechst 33342 in PBS was added for 5 min at room 
temperature and cells were washed again. S8L presentation was analysed by 
microscopy using an Olympus IX81 microscope. Analysis of the mean fluorescence 
intensity of 25D1.16 staining was performed using the Olympus SCAN^R software. 
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3.2.13.2 Microscopical analysis of neuron-microglial cocultures 
After 24 h of neuron-micrgolial coculture, the supernatant was slowly sucked off, cells 
were washed carefully two times with PBS, and staining was performed at room 
temperature. Cells were fixed in 4 % PFA for 15 min, subsequently blocked with 
blocking solution II for 1 h, and stained with the primary antibodies against β-tubulin 3 
(for detection of neurons) and Iba1 (for detection of microglia) added in blocking 
solution II for 2 h. Afterwards, cells were washed three times with PBS, the secondary 
antibodies goat-anti-mouse-Cy3 (neurons) and goat-anti-rabbit-Alexa488 were added 
for 2 h in blocking solution II, and finally, after three wash steps with PBS, cover slides 
were fixed with Mowiol. Cells were examined under an Olympus IX81. Ten randomly 
selected areas were scanned and relative neuronal neurite density was calculated by 
counting all β-tubulin 3 positive neurites that crossed three parallel lines per image. The 
mean neurite density per area was determined and afterwards the mean neurite density 
per sample, i.e. per 10 randomly selected areas, was calculated. The relative neuronal 
neurite density of cocultures with untreated C57BL/6 primary microglia served as 
control and was set as 1. 
3.2.14 Experimental autoimmune encephalomyelitis (EAE) 
EAE was induced by s.c. injection of 50 µg MOG35-55 peptide emulsified in complete 
Freund’s adjuvant with 8 mg/ml heat-inactivated Mycobacterium tuberculosis and two 
intraperitoneal (i.p.) injections of 100 ng Bordetella pertussis toxin on days 0 and 2. 
Clinical assessment of EAE was performed daily using a scale ranging from 0 to 8: 0, 
no paralysis; 1, limp tail; 2, ataxia or unilateral hind limb paresis; 3, severe unilateral or 
weak bilateral hind limb paresis; 4, severe bilateral hind limb paresis; 5, complete 
bilateral hind limb plegia; 6, complete bilateral hind limb plegia and partial fore limb 
paresis; 7, severe tetraparesis/plegia; 8, moribund/dead animals. 
3.2.15 Isolation of CNS mononuclear cells 
For mononuclear cell isolation from the CNS of EAE-diseased mice, mice were 
anesthesised with Avertin and then perfused with 25 ml of GBSS and heparin. 
Afterwards the brain was carefully dissected from the skull and the spinal cord was 
flushed out of the spinal column with GBSS containing heparin employing a 20 G 
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needle attached to a 10 ml syringe. Brain and spinal cord were dissected, taken up in 
10 ml of 0.4 mg / ml CollagenaseA in PBS, and left for 30 min at 37°C for tissue 
digestion in a rotary shaker. Then, the tissue was homogenised by pressing it through a 
metal cell strainer and cells were washed once with icecold PBS + 1 % FCS. 
Subsequently, cells were resuspended in 2.5 ml of 30 % Percoll and a gradient was 
created by underlayering the cell suspension with 2.5 ml of 37 % Percoll solution which 
was subsequently underlayered with 2.5 ml of 70 % Percoll solution. The gradient was 
centrifuged for 30 min at 859 × g with acceleration 7 and break 1. Mononuclear cells 
were collected from the 30 % : 37 % as well as the 37 % : 70 % interface and washed 
two times with icecold PBS + 1 % FCS. In case of analysis of myeloid cell surface 
markers, cells were resuspended in FACS buffer and staining was performed as 
described in 3.2.2.1. For analysis of T cell cytokine production by intracellular FACS 
staining (3.2.2.3), cells were resuspended in T cell medium containing 5 ng/ml PMA 
and 200 ng/ml IONO as well as 1 µl/ml of both, BrefeldinA and Monensin. For 
ELISPOT analysis of T cells (3.2.7), cells were resuspended in T cell medium. 
3.2.16 Histology  
For histological staining, the CNS of diseased mice was perfused with 25 ml of GBSS 
containing heparin and afterwards fixed by perfusion with with 25 ml 4 % PFA. Next, 
the brain was carefully dissected from the skull and the spinal chord was isolated and 
stored in 4 % PFA. Immunohistochemistry of the spinal chord was kindly performed by 
Dr. Ildiko Dunay and Prof. Marco Prinz (Department of Neuropathology, University of 
Freiburg, Germany) as described42. To determine the degree of demyelination, three 
slices of the spinal chord were stained with luxol fast blue (LFB) and afterwards 
incubated with Schiff reagent which stains demyelinated areas in pink. To quantify the 
percentage of demyelinated area, the total area as well as the proportion of 
demyelinated area per section was analysed using the Cell Analysis Software. To detect 
axonal damage, sections were stained for amyloid precursor protein (APP) and APP 
deposits were counted. Immunohistochemical staining of MAC-3 was performed to 
detect CNS-resident microglia and infiltrating macrophages and CD3 to detect T cells. 
For quantification, numbers of APP deposits or immune cells were applied to the total 
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area in mm2 per section. Three sections per animal were analysed with 5 mice per 
group. 
3.2.17 Ablation of CCR2+ inflammatory monocytes 
CCR2+ inflammatory monocytes were depleted during EAE by i.p. injection of 20 
µg αCCR2 (MC-21) or Isotype Control (Rat IgG2b). Antibodies were administered 
every 24 h from days 13 to 17 post EAE-induction. 8 h after the first injection, depletion 
of inflammatory monocytes, i.e. CD11b+Ly-6ChiLy-6G- cells, was monitored in the 
blood by flow-cytometry (3.2.2.1).  
3.2.18 Monocyte differentiation experiments 
3.2.18.1 In vivo labelling of Ly-6Chi monocytes 
EAE was induced in C57BL/6 mice (3.2.14). On day 12 after immunisation, mice were 
administered 200 µl clodronate liposomes by i.v. injection which results in depletion of 
blood monocytes or received PBS liposomes as control. 12 h later, i.e. during the time 
of leukocyte reconstitution, mice received 0.5 µm Flouresbrite FITC-dyed polystyrene 
beads diluted 1:25 in PBS by i.v. injection. Another 12 h later, CNS mononuclear cells 
were isolated (3.2.15) and infiltrating FITC+ monocytes were analysed for CD45 
expression by flow-cytometry (3.2.2.1). 
3.2.18.2 Adoptive transfer of CD45.2+ monocytes  
EAE was induced in CD45.1 mice (3.2.14). On day 12, CD115+ monocytes were 
isolated from the bone marrow of congenic mice for adoptive transfer. To this end, bone 
marrow cell suspensions from C57BL/6 mice (CD45.2+) were centrifuged at 486 × g for 
5 min and afterwards resuspended in 40 µl MACS buffer per 1x107 cells which 
contained 10 µl/ml αCD16/CD32 to block Fcγ receptors. Cells were incubated for 
10 min at room temperature after which 100 ng of biotinylated αCD115 per 1x106 cells 
was added to the cell suspension and further incubated for 10 min at room temperature. 
After addition of MACS buffer and centrifugation for 10 min at 486 × g, cells were 
incubated with 80 µl MACS buffer + 20 µl αbiotin microbeads per 1x107 cells for 
15 min at 4°C. Subsequently, cells were washed once with MACS buffer, resuspended, 
and separated by positive selection using the AutoMACS Separation Technology. 
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Isolated cells were analysed by flow-cytometry for CD11b and Ly-6C expression 
(3.2.2.1). Cells were counted and the percentage of CD11b+Ly-6C+ cells was applied to 
the total cell number to calculate the number of isolated Ly-6C+ monocytes. Finally, 
1x107 Ly-6C+ monocytes in 200 µl PBS were adoptively transferred by i.v. injection 
into recipient mice. 12 h after monocyte transfer, CNS mononuclear cells were isolated 
(3.2.15) and transferred CD45.2+ monocytes were analysed for CD45 expression 
(3.2.2.1).  
3.2.19 Statistics 
Results are depicted as mean ± standard error of the mean (SEM). Statistical 
significance was calculated by an unpaired two-tailed Student’s t test using Microsoft 
Excel software. p values of 0.01 to 0.05 were considered significant (*), p values of 
0.001 to <0.01 highly significant (**) and p of <0.001 extremely significant (***). 
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4 Results 
4.1 Impact of PPARγ activation in dendritic cells on cross-priming of 
cytotoxic T cells 
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that are capable 
of cross-presenting extracellular antigens on MHC-I molecules15,16 which is a 
prerequisite for the activation of antigen-specific naive CD8+ T cells. We and others 
have shown that DC immunogenicity and their capacity to activate CD4+ T cells is 
regulated by the nuclear transcription factor PPARγ. Activation of PPARγ interferes 
with inflammation-induced upregulation of costimulatory molecules like CD80, CD86, 
and CD40 as well as production of proinflammatory cytokines, e.g. IL-6 and IL-12, 
upon inflammatory stimulation of DCs78,79. This “less stimulatory mode” results in 
CD4+ T cell anergy79. However, if PPARγ is also involved in regulation of DC cross-
priming capacity and resulting antigen-specific CD8+ T cell responses is not known. 
Therefore, we investigated if PPARγ activation influences cross-presentation by DCs 
and subsequent activation of naive CD8+ T cells. 
4.1.1 The expression of the MR by DCs is increased after activation of 
PPARγ   
In this study we focused on the influence of PPARγ activation in DCs on mannose 
receptor (MR)-mediated cross-presentation of the soluble model antigen ovalbumin 
(OVA). Burgdorf et al. have demonstrated that the MR is essential for cross-
presentation of soluble OVA as MR-deficient BM-DCs were not capable of cross-
presenting OVA25,26 and furthermore, that the antiinflammatory nuclear transcription 
factor PPARγ was expressed primarily by MR+ DCs compared to MR- DCs (fold 
change of 2.74; p=0.0015)103 which is in line with previous observations by Coste et al. 
that have correlated PPARγ activation to increased levels of MR mRNA in DCs104.  
These reports led us to hypothesise that PPARγ activation in BM-DCs results in 
enhanced MR expression. Therefore, we differentiated bone marrow precursor cells in 
the presence of the synthetic PPARγ agonist pioglitazone (PIO) and analysed MR 
expression on day 7 by flow-cytometry. Indeed, we observed that PIO-treatment 
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resulted in an increased proportion of MR-expressing BM-DCs when compared to 
untreated DCs (Figure 1a,b). As PIO potentially could have mediated its effect in a 
PPARγ-independent fashion, we next investigated whether increased expression levels 
of the MR were still observed in PIO-treated PPARγKO BM-DCs. To this end, we 
generated conditional PPARγΚΟ BM-DCs in vitro by treatment of bone marrow 
precursor cells derived from PPARγfl/fl mice with a membrane-permeable Cre-
recombinase (HTNCre) which leads to deletion of exon 1 and 2 and thus a non-
functional PPARγ gene in 70-80 % of all cells79,100. Importantly, PIO-treatment of 
conditional PPARγΚΟ DCs did not result in significant upregulation of the MR as 
observed in HTNCre-treated wildtype BM-DCs (Figure 1c,d). Thus, activation of 
PPARγ in DCs by PIO-treatment increases the proportion of MR-expressing cells which 
is mediated by PPARγ-dependent effects of PIO.   
 
Figure 1 PPARγ  activation in BM-DCs results in upregulation of the MR. 
(a) Wildtype (wt) or MR-deficient (MR-/-) BM-DCs were treated with 10 µM PIO during the 
differentiation procedure or were left untreated. On day 7, MR expression was analysed by flow-
cytometry. (b) Graphs show the analysis of histograms in (a); i.e. the mean percentage of MR+ BM-DCs 
(upper panel) ± SEM and the average mean fluorescence intensity (MFI; lower panel) ± SEM. (c+d) Bone 
marrow precursor cells were isolated from wt or PPARγfl/fl mice and treated for 6 h with HTNCre on days 
0 and 4 of the differentiation procedure. Due to this procedure, PPARγ was ablated in PPARγfl/fl BM-DCs 
but not in wt BM-DCs (c+d; –HTNCre: left panel; +HTNCre: right panel). 10 µM PIO was added to the 
appropriate dishes. On day 7 of differentiation, MR expression was analysed by flow-cytometry. (c) The 
mean percentage of MR+ BM-DCs ± SEM or (d) the average MFI ± SEM is shown. Experiments were 
performed at least three times and data of one representative experiment is shown. * p<0.05; 
*** p<0.001. 
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4.1.2 PPARγ-activation in DCs enhances MR-mediated OVA-uptake  
We next asked whether the observed PPARγ-mediated upregulation of MR expression 
leads to enhanced uptake of soluble OVA as the MR mediates uptake of OVA in 
DCs25,26. To this end, we treated BM-DCs with PIO or left cells untreated and incubated 
these cells with fluorescently-labeled OVA. Flow-cytometrical analysis revealed that 
PIO-treated BM-DCs took up significantly more OVA when compared to untreated 
BM-DCs (Figure 2a,b). As MR-deficient BM-DCs did not take up OVA and we did not 
observe an increase in OVA uptake after PPARγ activation (Figure 2a,b), it can be 
concluded that increased uptake of OVA after PIO-treatment of wildtype BM-DCs was 
mediated by enhanced MR expression. To confirm that increased OVA-uptake after 
PIO-treatment was mediated by PPARγ-dependent effects of PIO, we repeated the 
experiment in conditional PPARγKO BM-DCs. We observed that ablation of PPARγ in 
BM-DCs abrogated the differences that were observed in PIO-treated compared to 
untreated wildtype BM-DCs and uptake of OVA was not enhanced in PIO-treated 
PPARγKO BM-DCs (Figure 2c,d). Thus, these data demonstrate that PPARγ activation 
after PIO treatment was responsible for the observed increase in MR-mediated OVA 
uptake. 
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Figure 2 PPARγ-mediated increase of MR expression results in enhanced MR-mediated 
uptake of OVA.   
(a) PIO-treated or untreated wt or MR-/- BM-DCs were incubated with 3 µg/ml AlexaFluor647-labelled 
OVA at 37°C. After 15 min, OVA uptake was determined by flow-cytometrical analysis. (b) Graphs 
show the analysis of histograms in (a); i.e. mean percentage of OVA+ BM-DCs (upper panel) ± SEM and 
the average MFI (lower panel) ± SEM. (c+d) Bone marrow precursor cells were isolated from wt or 
PPARγfl/fl mice and treated for 6 h with HTNCre on days 0 and 4 of the differentiation procedure. During 
this procedure, PPARγ was ablated in PPARγfl/fl BM-DCs but not in wt BM-DCs (c+d; –HTNCre: left 
panel; +HTNCre: right panel). 10 µM PIO was added to the appropriate dishes. On day 7 of 
differentiation, OVA uptake experiments were performed as in (a) and uptake was analysed by flow-
cytometry. (c) The mean percentage of OVA+ BM-DCs ± SEM or (d) the average MFI ± SEM is shown. 
Experiments were performed at least three times and data of one representative experiment is shown. 
* *p<0.01; *** p<0.001. 
4.1.3 Increased OVA-uptake after PPARγ  activation in DCs results in 
enhanced OVA cross-presentation    
As Burgdorf et al. have shown that soluble OVA, which has been taken up via the MR, 
is cross-presented on MHC-I molecules25, we hypothesised that the observed PPARγ-
induced increase in MR-mediated uptake of soluble OVA leads to enhanced cross-
presentation of OVA by DCs. To this end, we incubated PIO-treated or untreated BM-
DCs with purified OVA for 16 h. Then, OVA-loaded BM-DCs were stained with the 
antibody 25-D1.16 which binds to the OVA-derived epitope SIINFEKL (S8L) when 
complexed to the MHC-I molecule Kb 25,105-108. We performed microscopical analysis of 
OVA-loaded BM-DCs using the Scan^R software to determine the mean fluorescence 
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intensity (MFI) of 25-D1.16 staining and hence the amount of cross-presented OVA. 
Importantly, we observed that PIO-treated BM-DCs exhibited significantly enhanced 
MFI of α25-D1.16-staining compared to untreated DCs (Figure 3a) which demonstrates 
that cross-presention of OVA was enhanced after PPARγ activation. In a second 
approach we incubated PIO-treated or untreated DCs with soluble OVA and 
subsequently cocultured OVA-loaded DCs with the T cell hybridoma B3Z which 
recognises S8L in the context of MHC-I Kb 109 and does not depend on costimulatory 
signals for activation109-111. Importantly, activated B3Z cells produce β-galactosidase 
under control of the IL-2 promoter whose activity directly correlates with the amount of 
cross-presented S8L. As shown in Figure 3b, we observed that coculture with PIO-
treated BM-DCs resulted in significant increased activation of B3Z cells confirming that 
PPARγ-activation in DCs indeed resulted in enhanced levels of cross-presented OVA. 
Taken together, PPARγ activation by PIO led to upregulation of the MR in DCs which 
resulted in enhanced uptake of soluble OVA and in turn cross-presented OVA-derived 
peptides.  
            
  
Figure 3  Increased OVA-uptake after PPARγ  activation in DCs results in enhanced OVA 
cross-presentation.  
(a) Wildtype BM-DCs were treated with 10 µM PIO or left untreated. On day 6 of the differentiation 
procedure, 10 mg/ml purified OVA was added overnight. For detection of cross-presented OVA, BM-
DCs were stained with a biotinylated 25-D1.16 antibody and Alexa647-labelled Streptavidin. The MFI of 
25-1.16 staining was analysed using the SCAN^R software from Olympus. The graph shows the average 
MFI ± SEM. (b) PIO-treated or untreated BM-DCs were cocultured with B3Z cells at a ratio of 1:2 (BM-
DC:B3Z) in the presence or absence of 0.5 mg/ml purified OVA. After 24 h, CPRG solution was added to 
the cells and activation of B3Z cells was determined by spectophotometric analysis of CPRG-conversion 
at 595 nm. The graph shows the mean optical density at 595 nm (OD595) ± SEM. (Experiment performed 
by Luisa Klotz). All experiments were performed at least 3 times. Data of one representative experiment 
are shown. Within one experiment, n ≥ 3. *** p<0.001. 
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4.1.4 PPARγ-activation in DCs results in impaired antigen-specific CD8+ 
T cell activation 
As PIO-mediated activation of PPARγ in DCs resulted in enhanced levels of MR-
mediated uptake and increased levels of cross-presented OVA-peptides, we next asked 
whether also cross-priming of naive OVA-specific CD8+ T cells by PIO-treated BM-
DCs is altered. Therefore we made use of T cell receptor transgenic OT-I mice which 
express an OVA-specific T cell receptor that recognises the S8L epitope bound to 
MHC-I Kb. In contrast to B3Z cells, naive CD8+ OT-I T cells depend on constimulation 
and cytokines for full activation112. To investigate whether PPARγ activation affects 
priming of naive T cells, we set up coculture assays of PIO-treated or untreated BM-
DCs with naive OT-I T cells in the presence of 0.5 mg/ml purified OVA. After 48 h, we 
analysed the T cell activation status and determined IFN-γ secretion in the supernatant 
by ELISA and analysed the CFSE dilution profile by flow-cytometry to determine 
proliferation. As shown in Figure 4a and Figure 4b, PIO-treated DCs were strongly 
impaired in their capability to efficiently cross-prime naive CD8+ T cells as T cells 
primed by PIO-treated BM-DCs produced significantly less IFN-γ through a range of 
DC:T cell ratios (Figure 4a) and exhibited impaired proliferation (Figure 4b). As these 
results suggested that naive OT-I T cells were not appropriately activated, we next 
performed an in vitro cytotoxicity assay which allows to analyse the cytotoxicity of 
CD8+ T cells and hence, whether T cells had acquired effector functions during priming. 
To this end, OT-I T cells were isolated after 5 days of priming by PIO-treated or 
untreated BM-DCs using density gradient centrifugation and subsequently incubated 
with CFSE-labelled, S8L-loaded target cells. Lysis of target cells and hence, the 
capability of OT-I T cells to perform effector functions, was analysed after 4 h by flow 
cytometry. Importantly, OT-I T cells primed by PIO-treated BM-DCs exhibited 
significantly reduced cytotoxic capacity compared to OT-I T cells activated by 
untreated DCs (Figure 4c) which demonstrates that, although PPARγ activation results 
in enhanced cross-presentation of OVA, naive T cell priminig is impaired.   
We wondered whether this impairment in activation of OVA-specific T cells can also be 
observed during reactivation of OVA-specific CD8+ memory T cells. To this end, we 
adoptively transferred naive CD45.2+ OT-I T cells into CD45.1+ recipient mice which 
were infected one day later with an OVA-expressing adenovirus to generate memory 
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CD8+ T cells. 30 days post infection, we isolated CD45.2+ cells, i.e. OVA-specific 
memory CD8+ T cells, cocultured them ex vivo with OVA-loaded, PIO-treated or 
untreated BM-DCs and determined IFN-γ production by ELISA. Importantly, PPARγ 
activation in BM-DCs did not influence their reactivation capacity as memory T cells 
were equally well reactivated by PIO-treated or untreated DCs and produced similar 
amounts of IFN-γ (Figure 4d).  
Taken together, PPARγ activation in DCs impairs activation of naive CD8+ T cells and 
subsequent differentiation into effector T cells. In contrast, reactivation of established 
CD8+ T cell responses remains unaffected. 
 
 
Figure 4  PPARγ-activation in DCs results in impaired antigen-specific CD8+ T cell  
 activation. 
(a) Wildtype BM-DCs were treated with 10 µM PIO or left untreated and subsequently cocultured with 
naive OVA-specific CD8+ T cells derived from OT-I mice in the presence of 0.5 mg/ml OVA at the 
indicated DC:T cell ratios. After 48 h, the concentration of IFN-γ in the supernatant was determined by 
ELISA. The mean concentration of IFN-γ ± SEM is depicted. (Experiment performed by Sven Burgdorf). 
(b) PIO-treated or untreated BM-DCs were cocultured with CFSE-labelled OT-I T cells as described in 
(a) at a ratio of 1:2 (DC:OT-I). After 72 h, flow-cytometrical analysis of CFSE-dilution was performed. 
Within histograms, the mean division index (DI) ± SEM and the percentage of divided cells (% div) ± 
SEM is shown on the left side and the average percentage of cells per cycle is shown above the graph. (c) 
OT-I T cells were isolated after 5 d priming by PIO-treated or untreated BM-DCs and incubated at the 
indicated target cell:T cell ratios with OVA-peptide-loaded CFSE-labelled target cells. 4 h later, the 
OVA-specific cytotoxicity was analysed by flow-cytometry. The mean OVA-specific cytotoxicity ± SEM 
is shown. (d) CD90.2+ OT-I T cells were adoptively transferred into congenic CD90.1 mice 24 h before 
infection with an OVA-expressing Adenovirus. After 30 d, CD90.2+ memory T cells were isolated by 
immunomagnetic separation and ex vivo restimulated by PIO-treated or untreated, OVA-loaded BM-DCs. 
18 h later, reactivation of memory T cells was determined by detection of IFN-γ in the supernatant by 
ELISA. The graph shows the mean concentration of IFN-γ ± SEM. All experiments were performed at 
least 2 times. Data of one representative experiment are shown. Within one experiment, n ≥ 3. * p<0.05; 
** p<0.01.  
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4.1.5 Enhanced B7H1 expression after activation of PPARγ  in DCs restricts 
priminig of naive CD8+ T cells  
PPARγ activation in DCs interferes with upregulation of costimulatory molecules and 
cytokine production upon inflammatory stimulation78,79. Therefore we next asked 
whether impaired priming of naive OVA-specific OT-I T cells by PIO-treated, naive 
BM-DCs was the result of a change in expression of coinhibitory and costimulatory 
molecules and compared expression on PIO-treated or untreated BM-DCs by flow-
cytometrical analysis. We observed a significantly enhanced expression of the 
coinhibitory molecule B7H1 on PIO-treated BM-DCs (Figure 5a). Furthermore, when 
we incubated PIO-treated or untreated BM-DCs with fluorescently-labelled OVA, we 
observed that OVA uptake and hence MR expression correlated with B7H1 expression 
and that the proportion of B7H1+OVA+ BM-DCs was increased among PIO-treated 
compared to untreated BM-DCs (Figure 5b). Interestingly, the expression of 
costimulatory molecules, i.e. CD40, CD80, CD86, and ICOSL, was not significantly 
altered due to PIO-treatment (Figure 5c) which strongly suggests that a change in 
conhibition but not costimulation is the reason for impaired priming of naive CD8+ T 
cells by PIO-treated DCs. However, as the coinhibitory molecule B7DC was only 
marginally expressed on immature BM-DCs and not altered in response to PIO-
treatment (Figure 5d) our data strongly indicate that B7H1 is the main mediator of 
PPARγ-induced impairment of naive CD8+ T cell priming. 
 
 
Figure 5  PPARγ  activation leads to enhanced expression of B7H1 but not to changes in 
other costimulatory and coinhibitory molecules. 
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(a) BM-DCs were treated with 10 µM PIO or left untreated, stained for B7H1, and analysed by flow-
cytometry. The accompanying graph depicts the average MFI of B7H1 expression ± SEM. (b) PIO-
treated or untreated BM-DCs were incubated with 3 µM Alexa647-labelled OVA for 15 min at 37°C. 
Subsequently, cells were stained for B7H1, and analysed by flow-cytometry. Numbers in dotplots 
represent the mean percentage of B7H1+OVA+ BM-DCs ± SEM. (c,d) PIO-treated or untreated BM-DCs 
were stained for expression of (c) costimulatory molecules CD80, CD86, CD40, and ICOSL and (d) the 
coinhibitory molecule B7DC and analysed by flow-cytometry. All experiments were performed at least 2 
times. Data of one representative experiment are shown. Within one experiment, n ≥ 3. *** p<0.001. 
 
We next investigated whether the observed upregulation of B7H1 was responsible for 
PIO-induced impairment of naive CD8+ T cell activation. To this end, we treated B7H1-
deficient BM-DCs with PIO or left cells untreated which were then cocultred with OT-I 
T cells. To determine T cell activation we measured IFN-γ production in the supernatant 
by ELISA and analysed CFSE dilution profiles by flow-cytometry. Importantly, T cells 
primed by PIO-treated B7H1-deficient BM-DCs produced significantly higher amounts 
of IFN-γ (Figure 6a) and exhibited strongly increased proliferation (Figure 6b). Hence, 
as PIO-treatment in the absence of B7H1 resulted in increased T cell priming in vitro, 
these data strongly suggest that the impaired T cell priming capacity of PIO-treated 
wildtype BM-DCs was mediated by upregulation of B7H1.  
As coinhibitory signalling of B7H1 expressed by APCs is mediated by interaction with 
PD-1 expressed on the T cell surface28 we next hypothesised that the interference with 
B7H1 – PD-1 interaction during coculture experiments will restore the capacity of PIO-
treated wildtype BM-DCs to activate naive CD8+ T cells. To this end, we first 
confirmed PD-1 expression on freshly isolated OT-I T cells by flow-cytometry 
(Figure 6c). Then, we set up coculture assays of PIO-treated or untreated wildtype BM-
DCs with naive OT-I T cells and specifically blocked the interaction of B7H1 and PD-1 
by adding a PD-1-specific antibody92 (right graph) or the appropriate isotype control 
(left graph). Importantly, we observed that blocking the interaction of PD-1 and B7H1 
abrogated the impairment of PIO-treated DCs to cross-prime naive CD8+ T cells as 
T cells primed by PIO-treated DCs produced slightly enhanced levels of IFN-γ when 
compared to T cells primed by untreated DCs (Figure 6d).  
To summarise, these data demonstrate that impaired cross-priming capability of BM-
DCs after PPARγ activation is mediated by upregulation of B7H1 on APCs and its 
interaction with PD-1 expressed on the T cell surface. 
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Figure 6 Upregulation of B7H1 in PPARγ-activated BM-DCs restricts cross-priming of 
naive OT-I T cells. 
(a) BM-DCs were generated from B7H1-deficient mice and treated with 10 µM PIO or left untreated. 
BM-DCs were cocultured with OVA-specific OT-I T cells at a ratio of 1:2 (BM-DCs:OT-I) in the 
presence or absence of 0.5 mg/ml purified OVA and T cell activation was determined by quantification of 
IFN-γ in the supernatant by ELISA. The average IFN-γ concentration ± SEM is shown. (b) PIO-treated or 
untreated B7H1-deficient BM-DCs were cocultured with CFSE-labelled OT-I T cells to determine T cell 
proliferation. After 48 h, the CFSE dilution profile was analysed by flow-cytometry. Numbers on the left 
side in histograms display the mean division index (DI) ± SEM and average percentage of divided cells 
(% div) ± SEM. Numbers above the histogram show the mean percentage of cells within one cycle. (c) 
OT-I T cells were isolated from spleen and lymph nodes of OT-I mice, stained for PD-1, and analysed by 
flow-cytometry. (d) PIO-treated or untreated wldtype BM-DCs were cocultured with OT-I T cells at a 
ratio of 1:2 (BM-DCs:OT-I) in the presence of 20 µg/ml PD-1 blocking antibody or isotype control. After 
18 h, T cell activation was determined by detection of IFN-γ in the supernatant by ELISA. The mean 
concentration of IFN-γ ± SEM is depicted. All experiments were performed at least 2 times and data of 
one representative experiment is shown. * p<0.05. 
4.1.6 Activation of PPARγ  in splenic DCs impairs cross-priming of naive 
CD8+ T cells in vivo by upregulation of B7H1 
Next, we asked the question whether the observed effect of PPARγ activation on cross-
presentation by BM-DCs in vitro is also observed after PPARγ activation in DCs in 
vivo. Therefore we administered 30 mg/kg bodyweight PIO or the vehicle only to 
C57BL/6 mice by daily oral gavage for 7 days. First we investigated whether PIO-
treatment changes MR-expression and MR-mediated OVA-uptake in splenic DCs. To 
this end, PIO-treated or untreated mice were injected with 5 µg/g bodyweight 
fluorescently-labelled OVA, splenic CD11c+ DCs were isolated 45 min later, and DCs 
were analysed with regard to OVA-uptake as well as MR-expression by flow-
cytometry. We observed that also in vivo, PIO-treatment increased the proportion of 
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MR-expressing DCs and enhanced OVA-uptake (Figure 7a) thus, confirming our in 
vitro findings in PIO-treated BM-DCs.  
Next, we hypothesised that enhanced uptake of OVA following PIO-treatment in vivo in 
turn results in increased cross-presentation of OVA. To this end, PIO-treated or 
untreated wildtype mice were injected with 100 µg/g bodyweight purified OVA. 45 min 
later, splenic DCs were isolated, cocultured with B3Z cells, and activation of B3Z cells 
was determined by spectophotometric analysis of CPRG-conversion. Importantly, PIO-
treated splenic DCs not only exhibited increased MR-mediated OVA-uptake but 
furthermore, activated B3Z cells more efficiently than untreated DCs (Figure 7b). Thus, 
these observations demonstrate that also in vivo, PPARγ activation in DCs results in 
increased cross-presentation of OVA. 
As our in vitro findings showed that PIO-treated BM-DCs were impaired in their 
capacity to prime naive OT-I T cells we next wanted to investigate whether in vivo PIO-
treatment changes the cross-priming ability of splenic DCs. To this end, we isolated 
splenic DCs from PIO-treated or untreated wildtype mice and cocultured these ex vivo 
with naive OT-I T cells in the presence of 0.5 mg/ml purified OVA. We determined 
T cell activation by measuring the amount of IL-2 and IFN-γ in the supernatant by 
ELISA. In line with our observations in cocultures of BM-DCs and OT-I T cells, we 
observed that T cells primed by PIO-treated splenic DCs produced significantly reduced 
amounts of IL-2 and IFN-γ hence suggesting that T cells were not properly activated 
(Figure 7c; Priming). Importantly, this difference in cytokine production was still 
observed when we restimulated equal numbers of OT-I T cells with αCD3 for 24 h 
following isolation from cocultures after 5 days (Figure 7c; Restimulation). These data 
strongly suggested that naive CD8+ T cells primed by PIO-treated splenic DCs did not 
undergo functional differentiation into effector cells. This led us to investigate the 
cytotoxic activity of CD8+ T cells in vivo and performed an in vivo cytotoxicity assay113. 
To this end, we injected PIO-treated, OVA-loaded BM-DCs s.c. into PIO-treated mice 
or untreated, OVA-loaded BM-DCs into vehicle-treated mice. 5 days later, we injected 
1x107 fluorochrome-labelled target cells i.v. that were loaded with the OVA-derived 
peptide S8L in order to determine antigen-specific cytotoxicity. Analysis of the specific 
elimination of S8L-loaded target cells in the draining lymph nodes revealed that in PIO-
treated mice, S8L-loaded target cells were not lysed whereas OVA-specific cytotoxicity 
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was detected in vehicle-treated animals (Figure 7d). Taken together, these data 
demonstrate that in vivo activation of PPARγ in DCs strongly impaired CD8+ T cell 
activation and their differentiation into effector T cells.  
In vitro we showed that PPARγ activation in BM-DCs resulted in enhanced B7H1 
expression which was responsible for the impairment of DCs to efficiently cross-prime 
cytotoxic T cells. Therefore, we next asked whether also in vivo B7H1 upregulation 
after PIO-treatment mediates impairment of naive CD8+ T cell priming. To this end, we 
treated B7H1-deficient mice with PIO or the vehicle only, isolated splenic DCs on day 7 
of PIO-treatment, and cocultured them with OT-I T cells in the presence of OVA. 
Importantly, OT-I T cells were fully activated by PIO-treated B7H1-deficient DCs and 
produced similar amounts of IL-2 and IFN-γ during priming as well as after 
restimulation when compared to T cells primed by vehicle-treated B7H1-/- DCs 
(Figure 7e; Priming and Restimulation). Importantly, these data suggest that also in 
vivo, PIO-induced changes in the cross-priming capability of DCs were mediated by 
upregulation of B7H1.   
 
 
 
 
Figure 7  Activation of PPARγ  in splenic DCs impairs cross-priming of naive CD8+ T cells in 
vivo by upregulation of B7H1. 
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(a+b) C57BL/6 mice were treated with 30 mg/kg PIO or the vehicle only by daily oral gavage. On day 7 
of PIO-treatment, mice received (a) 5 µg/g body weight Alexa647-labelled OVA or (b) 100 µg/g body 
weight purified OVA by i.v. injection. 45 min later, splenic CD11c+ DCs were isolated by 
immunomagnetic separation. (a) DCs were analysed for OVA uptake and MR expression by flow-
cytometry. The graph shows the average percentage of MR+OVA+ splenic DCs ± SEM. (b) DCs were 
cocultured with B3Z cells at a ratio of 1:2 (DCs:B3Z). Activation of B3Z cells was determined by 
spectophotometric analysis of CPRG conversion at 595 nm 24 h later. The mean optical density at 
595 nm (OD595) ± SEM is depicted. (c) On day 7 of PIO-treatement, splenic CD11c+ DCs were 
cocultured with OT-I T cells at a ratio of 1:2 (DC:OT-I) in the presence of 0.5 mg/ml OVA. After 48 h, 
the amount of IL-2 and IFN-γ was analysed in the supernatant by ELISA to determine T cell activation 
(Priming). On day 5 of coculture, T cells were isolated by density gradient centrifugation and 
restimulated in the presence of 4 µg/ml platebound αCD3 for 24 h after which the concentration of IL-2 
and IFN-γ was determined in the supernatant by ELISA (Restimulation). Graphs depict the mean 
concentration of each cytokine ± SEM. (Experiment performed by Luisa Klotz). (d) On day 7 of PIO-
treatment, mice received 1x106 OVA-loaded, PIO-treated BM-DCs whereas vehicle-treated mice received 
1x106 OVA-loaded, untreated BM-DCs by subcutaneous injection. After 5 d, the antigen-specific 
cytotoxicity was determined in vivo by transfer of 1x107 S8L-loaded, CFSEhi-labelled and analysis of 
specific elimination of S8L-loaded cells by flow-cytometry in the draining lymph nodes. Data is depicted 
as mean percentage of OVA-specific cytotoxicity ± SEM. (e) B7H1-deficient mice were treated with 
30 mg/kg PIO or with the vehicle only by daily oral gavage for 7 d. CD11c+ splenic DCs were cocultured 
with OT-I T cells as described in (c). The amount of IL-2 and IFN-γ in the supernatant was analysed by 
ELISA during priming and after restimulation. All experiments were performed at least 2 times. Data of 
one representative experiment are shown. Within one experiment, n ≥ 3. * p<0.05; ** p<0.01. 
 
4.1.7 Summary of chapter 6.1 
In the first part of this thesis we investigated whether activation of PPARγ in DCs 
influences cross-priming of naive CD8+ T cells. We demonstrated that treatment with 
the synthetic PPARγ agonist PIO resulted in increased expression of the MR in vitro 
and in vivo which strongly enhanced uptake of the soluble model antigen OVA and 
subsequent cross-presentation of OVA-derived peptides. However, despite increased 
levels of cross-presented antigen, naive CD8+ T cells were not properly activated and 
did not mature into cytotoxic effector cells. We revealed that PPARγ activation resulted 
in significant enhanced expression of the coinhibitory molecule B7H1 and that its 
interaction with the ligand PD-1 on T cells was responsible for the observed impairment 
of PIO-treated DCs to activate naive CD8+ T cells. To summarise, these findings 
demonstrate a new mechanism of DC-mediated tolerance induction in CD8+ T cells 
which potentially plays a role in inhibiting the activation of autoreactive CD8+ T cells.  
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4.2  PPARγ in myeloid cells plays an important role in limiting CNS 
inflammation during the effector phase of EAE 
Although autoreactive T cells are important for the initiation of EAE, the effector 
mechanisms leading to demyelination and inflammation within the CNS are likely to be 
provided by other cell types60. Indeed, several studies have highlighted the importance 
of myeloid cells, including CNS-resident microglia and infiltrating inflammatory 
monocytes and macrophages, for the perpetuation of disease. Heppner et al. showed that 
microglial paralysis results in delayed onset of disease and repression of clinical signs62. 
Mildner et al. demonstrated that inflammatory monocytes, which are recruited during 
autoimmune inflammation to the CNS, play an important role during the effector phase 
of disease and ablation of CCR2+ inflammatory monocytes results in amelioration of 
disease63. However, the main effector mechanisms contributing to CNS-inflammation 
and disease pathology are mediated by other cell types especially myeloid cells, i.e. 
monocytes, macrophages, and microglia62,63. As PPARγ has been shown to be a 
regulator of myeloid cell immunogenicity in vitro73,80,114, we hypothesised that during 
EAE, PPARγ in myeloid cells interferes with innate immune cell-mediated autoimmune 
inflammation in the CNS. 
4.2.1 PIO-treatment ameliorates EAE  
Treatment with the pharmacological PPARγ agonist pioglitazone (PIO) ameliorates the 
disease course in several mouse models of EAE90. We first thought to confirm these 
data and induced EAE in C57BL/6 mice by immunisation with MOG35-55 emulsified in 
complete Freund’s adjuvant and concomitantly treated mice with PIO or the vehicle 
only (CMC) by daily oral gavage. After immunisation, mice were clinically monitored 
which revealed that PIO-treatment resulted in significant amelioration of disease during 
the entire observation period, i.e. during the priming as well as the effector phase 
(Figure 8a).  
We next asked the question whether PIO-treatment affects the inflammatory milieu 
within the CNS. To this end, we isolated the mRNA from the upper cervical myelon of 
immunised PIO- or vehicle-treated mice during the effector phase, i.e. day 21 after 
induction of EAE, when myeloid cells play an important role for disease pathology63, 
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and analysed the expression levels of proinflammatory mediators, such as 
proinflammatory cytokines, inducible nitric oxide synthase (iNOS), and chemokines by 
quantitative real-time RT-PCR. As shown in Figure 8b, we observed significantly 
reduced expression levels of TNF-α, IL-12, and IL-23 in the CNS of PIO-treated mice 
compared to vehicle-treated animals and also expression levels of IL-1β and IFN-γ were 
decreased in the CNS of PIO-treated mice (Figure 8b). Moreover, expression levels of 
iNOS, the enzyme responsible for production of nitric oxide (NO), were reduced in the 
CNS of PIO- compared to vehicle-treated animals (Figure 8c). In addition, PIO-
treatment resulted in significantly diminished levels of CCL2, CCL3, and CXCL10 
(Figure 8d), chemokines which recruit macrophages and monocytes as well as activated 
T cells to the inflamed CNS, when compared to vehicle-treated animals. The T cell-
specific cytokines CCL5 and CCL20 were also reduced in the CNS of PIO-treated 
animals, however differences did not reach statistical significance (Figure 8d).  
To further characterise the ameliorative effect of PIO-treatment, we next investigated 
whether changes in the inflammatory milieu resulted in histopathological differences 
between PIO-treated and vehicle-treated mice. To this end, we isolated the CNS at a late 
stage of EAE, i.e. on day 35 after EAE induction, and performed immunohistological 
analysis of the spinal cord. We observed that the CNS of PIO-treated animals was 
characterised by significantly reduced demyelination and axonal damage (Figure 8e) as 
well as reduced numbers of Mac3+ cells, i.e. macrophages and microglia, and CD3+ 
T cells (Figure 8f) when compared to vehicle-treated animals.  
Taken together, PPARγ activation in vivo ameliorated clinical signs of EAE which is 
characterised by reduced inflammatory responses within the CNS and improved CNS 
pathology, i.e. diminished demyelination and axonal damage as well as decreased 
numbers of infiltrating cells.  
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Figure 8 PIO-treatment ameliorates clinical signs of EAE, reduces inflammatory responses 
within the CNS, and improves CNS pathology.  
(a) C57BL/6 mice were administered 30 mg/kg body weight PIO in 0.5 % carboxymethylcellulose 
(CMC) or the vehicle only (CMC) by daily oral gavage. MOG35-55-EAE was induced on day 7 of PIO-
treatment and mice were clinically monitored. The mean clinical score ± SEM of one representative 
experiment out of four experiments is depicted. (b-d) mRNA expression of (b) inflammatory cytokines, 
(c) iNOS, and (d) chemokines in the CNS of diseased PIO- or vehicle-treated C57BL/6 mice was 
determined by quantitative real-time RT-PCR on day 21 of EAE (n=10 per group). Data were normalised 
to endogenous GAPDH expression and are expressed as n-fold induction compared to healthy C57BL/6 
mice. Data are expressed as mean expression ± SEM. (e,f) Histopathological analysis of the spinal cord of 
PIO-treated or vehicle-treated (CMC) mice on day 35 of EAE. (e) shows demyelination (luxol fast blue 
(LFB)) and axonal damage (amyloid precursor protein (APP)) (n=5 per group); (f) depicts cell infiltrates 
(MAC-3 for macrophages/microglia; CD3 for T cells) (n=5). * p<0.05. 
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4.2.2 PPARγ is an important regulator of myeloid cells during the effector 
phase of EAE 
We hypothesised that the observed PIO-mediated amelioration of EAE is, at least in 
parts, due to activation of PPARγ in myeloid cells. However, as in vivo PIO-treatment 
targets all PPARγ-expressing cells we next wanted to confirm that PPARγ in myeloid 
cells is important for control of EAE.  
To answer this question we crossed mice that express the Cre recombinase under the 
Lysozyme M (LysM) promoter with mice that carry loxP sites within the PPARγ gene 
(PPARγfl/fl) resulting in the generation of conditional myeloid cell-specific PPARγ 
knockout mice (LysM-PPARγKO). To confirm a myeloid cell-specific PPARγ knockout 
in these mice, we analysed mRNA of different immune cell populations by RT-PCR 
which demonstrated that myeloid cells specifically lacked PPARγ as splenic CD11b+ 
cells including splenic macrophages, peritoneal macrophages, and  neutrophilic 
granulocytes expressed the truncated, non-functional 300 bp cDNA fragment of PPARγ 
whereas most DCs as well as T and B cells expressed the wildtype full-length 700 bp 
fragment of PPARγ cDNA (Figure 9a). To analyse the role of PPARγ in myeloid cells 
during EAE, we immunised LysM-PPARγKO mice or their wildtype littermates with 
MOG35-55 and monitored the course of disease. We observed that, in comparison to their 
WT littermates, the disease course in LysM-PPARγKO mice was significantly 
aggravated during the effector phase whereas the T cell-mediated induction phase was 
not altered (Figure 9b). This demonstrates that PPARγ in myeloid cells plays a crucial 
role in limiting the CNS-pathogenic potential of myeloid cells during the effector phase 
of EAE.  
Mildner et al. have demonstrated that inflammatory monocytes, characterised by 
expression of CCR2 and high levels of Ly-6C, are crucial for the effector phase of 
EAE63. As in LysM-Cre mice also monocytes are targeted by Cre-mediated 
recombination101 and LysM-PPARγKO mice exhibited an aggravated disease course 
during the effector phase of EAE, we hypothesised that the knockout of PPARγ in 
inflammatory monocytes is at least partially responsible for the observed differences 
between wildtype and LysM-PPARγKO mice. To assess the role of PPARγ in 
inflammatory monocytes, we selectively depleted CCR2+Ly-6Chi monocytes in the 
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circulation during EAE by injection of the αCCR2 antibody MC-2163,115,116. Again, we 
immunised LysM-PPARγKO mice or their wildtype littermates and clinically monitored 
the disease. We selectively depleted CCR2+Ly-6Chi inflammatory monocytes during the 
effector phase by repetitive injection of αCCR2 every 24 h between days 13 and 17 of 
EAE. Successful depletion of Ly-6Chi monocytes was confirmed 8 h after the first 
αCCR2-injection (Figure 9c). We observed that depletion of inflammatory monocytes 
resulted in amelioration of disease in both, LysM-PPARγKO mice and their wildtype 
littermates, and moreover, that the observed differences in disease severity between 
knockout and wildtype animals were completely abolished (Figure 9d).  
In summary, these data demonstrate that PPARγ plays an important role in limiting 
myeloid cell-mediated pathology during the effector phase of EAE. Importantly, we 
identified Ly-6Chi inflammatory monocytes as the central myeloid cell population 
regulated by PPARγ during EAE, as depletion of this population by αCCR2-treatment 
resulted not only in disease amelioration but abolished the observed differences in 
disease severity between LysM-PPARγKO mice and their wildtype littermates. 
 
 
Figure 9 PPARγ  in myeloid cells is important for control of the effector phase of EAE. 
 (Experiments performed in collaboration with Juliane Floßdorf) 
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(a) PPARγ was specifically ablated in cells of myeloid origin when PPARγfl/fl mice were crossed to 
LysM-Cre transgenic mice as shown by RT-PCR analysis of mRNA derived from primary microglia, 
splenic CD11b+ cells, peritoneal macrophages, and neutrophilic granulocytes, as well as splenic CD11c+ 
cells, T cells, and B cells. Cre-mediated recombination resulted in the expression of a truncated, non-
functional 300 bp cDNA fragment of PPARγ, when compared to wildtype full-length 700 bp fragment of 
PPARγ cDNA. (b) MOG35-55-EAE was induced by active immunisation of LysM-PPARγWT (n=12) or 
LysM-PPARγKO (n=13) mice, and mice were clinically monitored. The mean clinical score ± SEM of two 
representative out of five independent experiments is shown. (c+d)  EAE was induced by active 
immunisation of LysM-PPARγWT or LysM-PPARγKO mice. At the beginning of the effector phase i.e. 
from d13, mice received 5 injections (every 24 h; arrows) of 20 µg of αCCR2 antibody (MC-21; n=20 per 
group) or isotype control (RatIgG2b; n=15 per group). (c) Depletion of monocytes was monitored 8 h 
after the first injection in the blood. Live CD11b+ cells were gated and contourplots depict Ly-6C and Ly-
6G expression. Upper numbers within the contourplots indicate the percentage of CCR2-expressing Ly-
6ChiLy-6G- monocytes ± SEM (upper gate); lower numbers depict the percentage of Ly-6CloLy-6G- 
monocytes ± SEM (lower gate). Graph depicts the mean percentage of Ly-6Chi or Ly-6Clo monocytes ± 
SEM in the blood of αCCR2- or Isotype control-treated LysM-PPARγKO or LysM-PPARγWT mice. (d) 
Clinical score of immunised, αCCR2- or isotype control-treated mice. Arrows indicate days of injection. 
The mean clinical score ± SEM of two independent experiments is shown. * p<0.05; ** p<0.01; 
***p<0.001. 
 
4.2.3 Inflammatory monocytes migrate to the inflamed CNS and 
differentiate into macrophages and activated microglia 
The observation that ablation of CCR2+ monocytes completely abolished the difference 
in disease course of LysM-PPARγKO mice and their wildtype littermates was surprising, 
as knockout microglia residing behind the BBB were not targeted by this antibody. 
Although this indicates that the lack of PPARγ in microglia does not strongly contribute 
to the observed differences in the course of EAE between LysM-PPARγKO and LysM-
PPARγWT mice, we investigated a second explanation. We hypothesised that during 
EAE, infiltrating inflammatory monocytes differentiate not only into macrophages but 
also acquire a microglial phenotype thereby contributing to microglia-mediated 
neurotoxicty.  
To analyse whether inflammatory monocytes differentiate into microglia during EAE, 
we labelled circulating Ly-6Chi inflammatory monocytes in vivo on day 12 after EAE 
induction and analysed their phenotype after infiltration of the CNS. Labelling of 
Ly-6Chi monocytes was performed as described before64,117,118. After injection of 
clodronate liposomes, which leads to elimination of blood monocytes119, mice received 
FITC-labelled polystyrene beads during the time of leukocyte reconstitution, i.e. 12 h 
later. This resulted in labelling of circulating Ly-6Chi monocytes (Figure 10a) whereas 
mainly Ly-6Clo monocytes had taken up the administered FITC-beads in control mice 
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treated with PBS liposomes (Figure 10a). 12 h after bead injection, mononuclear cells 
were isolated from the CNS and FITC-labelled infiltrating monocytes were analysed for 
CD45 expression which is an established marker to discriminate between macrophages 
(CD45hi) and microglia, which express CD45 at low levels in a resting state and at 
intermediate levels, when they are activated118,120. To analyse the phenotype of 
infiltrating monocytes, we first identified macrophages and microglia by gating on live 
CD11b+ and Ly-6G- cells (Figure 10b). Within the population of macrophages and 
microglia we identified a distinct population of FITC+ cells derived from FITC-labelled 
inflammatory monocytes (Figure 10c). Further analysis of CD45 expression revealed 
that the majority of FITC+ cells were macrophages as characterised by high expression 
levels of CD45 (Figure 10d,e; red population). However, a small but distinct population 
displayed a microglial phenotype characterised by intermediate expression of CD45 
(Figure 10d,e; blue population).  
In a corresponding experiment we transferred bone marrow-derived CD115+CD45.2+ 
monocytes into EAE-diseased mice carrying the congenic marker CD45.1 on day 12 of 
EAE. 12 h after monocyte transfer, we analysed CNS infiltrating CD45.2+ monocytes 
with regard to CD45 expression. Again, we could demonstrate that within the 
population of transferred CD45.2+ monocytes a distinct subpopulation expressed CD45 
at intermediate levels suggesting that they had acquired the phenotype of activated 
microglial cells after entry into the inflamed CNS (Figure 10f). 
Taken together, these data reveal that inflammatory monocytes invading the CNS 
during ongoing autoimmunity acquire different phenotypes. Besides differentiation into 
macrophages, monocytes can also acquire a microglial phenotype characterised by 
intermediate expression of CD45. Importantly, these findings strongly suggest that 
inflammatory monocytes thereby also contribute to local microglial inflammatory 
responses and in consequence microglia-mediated disease pathology. 
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Figure 10  During EAE, inflammatory monocytes infiltrate the inflamed CNS and  
differentiate into macrophages and microglia.     
(a-e) MOG35-55 EAE was induced in C57BL/6 mice. On day 12 of EAE, mice were treated with 
clodronate- or PBS-lipsomes and 12 h later FITC-labelled 0.5 µm microsphere beads were administered 
i.v. (a) Another 12 h later, FITC-labelling of circulating CD11b+Ly-6G- monocytes was monitored by 
flow-cytometry. Contourplots depict Ly-6C expression and FITC-labelling. Upper numbers show the 
mean percentage of FITC+ cells within the population of Ly-6Chi monocytes; lower numbers show the 
mean percentage of FITC+ cells within the population of Ly-6Clo monocytes. (b) Gating strategy to 
identify the population of CD11b+Ly-6G- macrophages and microglia. (c) Identification of infiltrating 
monocytes by FITC expression. (d) CD45 expression of FITC+ cells. Numbers indicate the mean 
percentage of macrophage-like (red; CD45hi) or microglia-like (blue; CD45lo/int) cells among all FITC+ 
cells. (e) Graph depicts the mean percentage ± SEM of CD45hi or CD45int/lo cells within the population of 
FITC+ cells derived from clodronate-liposome-treated mice (n=5). (f) 1x107 CD115+CD45.2+ monocytes 
were immunomagnetically separated and adoptively transferred into EAE-diseased mice carrying the 
congenic marker CD45.1. 12 h after injection of monocytes, transferred monocytes isolated from the CNS 
were analysed by flow-cytometry for CD45 expression. The graph depicts the mean percentage ± SEM of 
CD45hi or CD45int/lo cells within the population of CD45.2+ transferred monocytes (n=5). 
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4.2.4 PPARγ impairs neurotoxic responses by myeloid cells 
We next wanted to characterise which inflammatory responses are regulated by PPARγ 
in myeloid cells with particular interest on factors that mediate neurotoxicity. To this 
end, we treated bone marrow-derived macrophages (BM-Ms) or primary microglia 
(pMg) with PIO, stimulated the cells with LPS ± IFN-γ, and analysed iNOS expression 
as well as production of nitric oxide (NO), reactive oxygen species (ROS), and 
proinflammatory cytokines.  
Stimulation of PIO-treated or untreated BM-Ms and pMg, with LPS and IFN-γ for 6 h 
and subsequent analysis by quantitative real-time RT-PCR revealed that PPARγ 
activation by PIO-treatment suppressed inflammation-induced upregulation of iNOS 
expression (Figure 11a). Concomitantly, PIO-treated macrophages and microglia 
produced significantly reduced amounts of NO in response to LPS and IFN-γ compared 
to untreated controls (Figure 11b). Importantly, also inflammation-induced production 
of ROS and TNF-α, both of which are strongly involved in immune-mediated 
demyelination in the CNS60, were significantly reduced in PIO-treated compared to 
untreated macrophages and microglia (Figure 11d). In line with these findings, we also 
observed that inflammation-induced production of IL-6 and IL-12 was significantly 
decreased in PIO-treated BM-Ms and pMg compared to untreated macrophages and 
microglia (Figure 11e,f).  
Taken together, these data reveal a potential neuroprotective role for PPARγ in myeloid 
cells as activation of PPARγ in macrophages and microglia interfered with 
inflammation-induced production of molecules that mediate neurotoxicity (NO, ROS, 
and TNF-α) or contribute to inflammatory processes, such as IL-6 and IL-12. These 
data suggest that PPARγ in myeloid cells is a regulator of innate immune responses 
within the CNS during ongoing autoimmune inflammation and that activation of PPARγ 
in myeloid cells limits demyelination and axonal damage (Figure 8e).  
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Figure 11  PPARγ  regulates neurotoxic responses by macrophages and microglia. 
For all experiments, bone marrow-derived macrophages (BM-Ms) or primary microglia (pMg) were 
pretreated with 10 µM PIO for 7 days. (a) PIO-treated or untreated BM-Ms or pMg were stimulated for 
6 h with 1 µg/ml LPS + 5 pg/ml IFN-γ (stim) and iNOS expression levels were determined by 
quantitative real-time RT-PCR. Data were normalised to endogenous GAPDH expression and are 
expressed as n-fold induction compared to unstimulated BM-Ms or pMg (w/o stim). (b) NO production 
by PIO-treated or untreated BM-Ms or pMg was measured after 48 h stimulation with 100 ng/ml LPS and 
1 µg/ml LPS, respectively, + 10 ng/ml IFN-γ by indirect measurement of nitrite levels by Griess Assay. 
(c) To determine the production of reactive oxygen species (ROS), PIO-treated or untreated BM-Ms were 
stimulated for 30 min with 100 ng/ml LPS. PIO-treated or untreated pMg were stimulated for 24 h with 
1 µg/ml LPS. After stimulation, 20 µM H2DCFDA in PBS was added and production of ROS was 
detected at 485 nm excitation and 530 nm detection. The induction of ROS is expressed as fold change in 
relative light units compared to the unstimulated control. (d,e) PIO-treated or untreated BM-Ms were 
stimulated with 100 ng/ml LPS. Production of (d) TNF-α and (e) IL-6 was determined in the supernatant 
by ELISA after 24 h and 48 h, respectively. (d,e) PIO-treated or untreated pMg were stimulated for 4 h 
with 1 µg/ml LPS + 5 pg/ml IFN-γ. Cells were intracellularly stained for (d) TNF-α or (e) IL-6 and 
analysed by flow cytometry. Numbers depict the average percentage of cytokine+ pMg ± SEM. (f) 
Expression of IL-12 in PIO-treated or untreated BM-Ms and pMg was determined as in (a). Shown is the 
mean ± SEM. Data of one representative of at least two independent experiments are shown, within one 
experiment n ≥ 3. * p<0.05; ** p<0.01; ***p<0.001. 
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4.2.5 PPARγ activation in myeloid cells suppresses neurotoxicity 
As PPARγ activation resulted in reduced production of neurotoxic mediators by 
myeloid cells (Figure 11), we next asked whether PPARγ activation in microglial cells 
indeed mediates neuroprotective effects. To this end, we stimulated PIO-treated or 
untreated pMg with LPS and IFN-γ ± PIO for 48 h. Activated microglia were cocultured 
with primary neurons for 24 h and the relative neurite density was analysed by 
microscopy in order to determine the degree of microglia-mediated neuronal damage. 
We observed that neurons cocultured with stimulated microglia exhibited significant 
reduced neurite density (0.64 ± 0.07; Figure 12a,b) when compared to neurons from 
cocultures with unstimulated pMg (Figure 12a,b). In contrast, coculture with PIO-
treated, stimulated microglia only resulted in a small and non-significant reduction of 
neurite density (0.86 ± 0.07) compared to unstimulated microglia (Figure 12a,b). 
Importantly, neurite density was significantly higher in cocultures with stimulated PIO-
treated microglia compared to untreated, stimulated microglia (Figure 12a,b). 
These data demonstrate that PPARγ activation in microglial cells interfered with 
production of neurotoxic factors in response to inflammatory stimulation, which indeed 
resulted in neuroprotection under inflammatory conditions.  
 
 
 
 
 
 
 
 
 
Figure 12  PPARγ  interferes with microglial neurotoxic responses.  
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PIO-treated or untreated primary microglia (pMg) were stimulated with 1 µg/ml LPS + 10 ng/ml 
IFN-γ for 48 h or were left untreated. 5x104 pMg were cocultured with 2.5x105 primary neurons for 24 h. 
(a) Neurons and microglia were fixed and double-immunostained with antibodies against tubulin-3 
(detects neurons; red signal) and Iba-1 (detects microglia; green signal). Scale bars: 100 µm. (b) 
Statistical analysis of neurite density depicted as mean neurite density ± SEM compared to unstimulated 
control (w/o PIO). Data of one representative experiment out of three independent experiments are 
shown. * p<0.05. 
4.2.6 During EAE, PIO-treatment reduces the immunogenic potential of 
CNS myeloid cells 
So far, we showed that during EAE the ameliorative effect of PPARγ activation in vivo 
is characterised by reduced demyelination and axonal damage and showed that PPARγ 
regulates neurotoxicity of macrophages and microglia in vitro. Next, we further 
investigated the impact of PPARγ activation on the immunogenicity of CNS 
macrophages and microglia in vivo. To this end, we isolated macrophages and microglia 
from the CNS of PIO- or vehicle-treated EAE-diseased mice during the effector phase, 
i.e. day 21 after immunisation, and analysed the expression of MHC-II and CD40 on 
these cells which play an important role in the reactivation of autoreactive T cells51,58,59. 
Becher et al. demonstrated that especially the presence of CD40 is important for the 
induction and perpetuation of EAE58. 
Macrophages and microglia, which are both CD11b+, are characterised by distinct 
expression of CD45 (Figure 10) and Ly-6C: macrophages are CD45hiLy-6C+ whereas 
microglia are CD45int/loLy-6Clo (Figure 13a). We observed that in PIO-treated animals 
MHC-II expression was significantly reduced on both, macrophages and microglia, 
when compared to CNS macrophages and microglia from vehicle-treated mice 
(Figure 13b). Whereas 25 % of macrophages derived from vehicle-treated mice 
expressed MHC-II, only 11.75 % of PIO-treated macrophages were MHC-II+ 
(Figure 13b) and this was also reflected in the mean fluorescence intensity (MFI) which 
was significantly reduced by 66 % on PIO-treated macrophages and by 60 % on PIO-
treated microglia (Figure 13b). Furthermore, the percentage of CD40-expressing CNS 
macrophages was reduced from 13.25 % in the CNS of vehicle-treated mice to 7.06 % 
in PIO-treated animals (Figure 13c) and the MFI of CD40 expression was reduced by 
52 % on PIO-treated macrophages (Figure 13c). However, CD40 was not expressed on 
microglia isolated from EAE-diseased mice and hence, no difference between PIO- and 
vehicle-treated mice could be observed (Figure 13c). To confirm that this effect was 
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mediated by PPARγ-dependent actions of PIO, we treated LysM-PPARγKO mice with 
PIO or vehicle only and analysed CNS macrophages for MHC-II and CD40 expression 
by flow cytometry. Importantly, we did not observe a reduction in expression of 
MHC-II or CD40 on PIO-treated LysM-PPARγKO macrophages indicating that the 
suppression of macrophage activation in wildtype mice during EAE by oral treatment 
with PIO was indeed mediated by in vivo activation of PPARγ in myeloid cells (Figure 
13d).  
Taken together, PPARγ activation regulates the immunogenicity of macrophages and 
microglia also in vivo, which is demonstrated by reduced upregulation of MHC-II and 
CD40 on CNS myeloid cells in response to the inflammatory milieu in the CNS of 
EAE-diseased PIO-treated mice.  
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Figure 13  PIO-treatment regulates the immunogenicity of CNS macrophages and microglia.  
(a-c) C57BL/6 mice or (d) LysM-PPARγKO mice were administered 30 mg/kg body weight PIO in 0.5 % 
CMC or the vehicle only by daily oral gavage. MOG35-55-EAE was induced on day 7 of PIO-treatment. 
Macrophages and microglia were isolated from the CNS of PIO- or vehicle-treated mice during the 
effector phase of EAE (day 21) and subsequently analysed by flow-cytometry. (a) Discrimination of CNS 
macrophages (CD11b+CD45hiLy-6C+) and microglia (CD11b+CD45loLy-6Clo). (b) Macrophages and 
microglia isolated from C57BL/6 mice were stained for (b) MHC-II (n=10) and (c) CD40 (n=9) 
expression (unstained control (tinted) and specific antibody (line)). Accompanying graphs depict the 
mean percentage ± SEM or the average mean fluorescence intensity (MFI) ± SEM. (d) Macrophages from 
LysM-PPARγKO were stained for MHC-II and CD40. Graphs depict the mean percentage of MHC-II- and 
CD40-expressing cells ± SEM (n=5 per group). * p<0.05; ** p<0.01. 
4.2.7 Reduced activation of CNS myeloid cells results in diminished T cell 
responses in the CNS 
So far we could show that in vivo PIO-treatment leads to diminished expression levels 
of cytokines important for reactivation of TH17 cells, such as IL-23 (Figure 8b), and 
TH1 cells, such as IL-12 (Figure 8b), in the CNS of diseased mice and importantly, that 
PPARγ activation in myeloid cells results in reduced expression of MHC-II and CD40 
by CNS macrophages and microglia (Figure 13b,c). As these data suggest that in vivo 
PIO-treatment creates a milieu within the CNS that interferes with local reactivation of 
encephalitogenic T cells we next characterised the CD4+ T cell responses within the 
CNS. 
To this end, we isolated T cells from the CNS of diseased PIO- or vehicle-treated mice 
during the effector phase of EAE and analysed the cytokine production after ex vivo 
restimulation with PMA/ionomycin by flow-cytometry. In addition, we determined the 
frequency of antigen-specific IL-17A-producing TH17 cells or IFN-γ-producing 
TH1 cells after restimulation with MOG35-55-loaded DCs by ELISpot analysis.  
We observed that CD4+ T cells isolated from the CNS of PIO-treated mice produced 
significantly less IL-17A after restimulation compared to CD4+ T cells isolated from the 
CNS of vehicle-treated animals (Figure 14a). Furthermore, CD4+ T cells produced 
reduced amounts of IFN-γ (Figure 14c), although this difference did not reach statistical 
significance.  
ELISpot analysis confirmed these findings and showed that the frequency of MOG-
specific IL-17A-producing CD4+ T cells was significantly reduced in PIO-treated 
animals with 154 ± 53.4 IL-17A+ spots per 3x104 CD4+ T cells compared to 503 ± 46.2 
IL-17A+ spots in vehicle-treated mice (Figure 14b). Moreover, the frequency of IFN-γ-
4  Results 73 
producing CD4+ T cells was reduced. Whereas in vehicle-treated animals 519 ± 83.8 
IFN-γ+ spots per 3x104 CD4+ T cells were observed, in PIO-treated animals only 
400 ± 97.3 IFN-γ+ spots were detected (Figure 14d).  
To summarise, PIO-mediated amelioration of the CNS inflammatory milieu, i.e. 
reduced expression levels of IL-12 and IL-23 as well as diminished surface expression 
of MHC-II and CD40 on CNS myeloid cells during the effector phase of EAE indeed 
resulted in reduced T cell responses within the CNS as the frequency and numbers of 
antigen-specific IL-17A- and IFN-γ-producing T cells were found to be reduced. 
However, the effect was more pronounced on TH17 cells.  
 
 
Figure 14  PIO-treatment results in reduced T cell activity during EAE within the CNS.  
C57BL/6 mice were administered 30 mg/kg body weight PIO in 0.5 % CMC or the vehicle only (CMC) 
by daily oral gavage. MOG35-55-EAE was induced and T cells were isolated from the CNS on day 21 of 
EAE. (a,c) CD4+ T cells were restimulated for 4 h with PMA/ionomycin prior to intracellular cytokine 
staining for IL-17A or IFN-γ and flow cytometric analysis. Gates in contourplots were set on cytokine+ 
CD4+ T cells. Graphs depict the mean percentage of cytokine-expressing CD4+ T cells ± SEM (n=5). 
(b,d) Isolated CD4+ T cells were restimulated with MOG35-55-loaded DCs and numbers of IL-17A and 
IFN-γ producing cells per 3x104 CD4+ T cells was determined by ELISpot-analysis. Graphs depict the 
mean number of cytokine-expressing CD4+ T cells per 3x104 CD4+ T cells ± SEM (n=6 per group; 
ELISpot analysis was performed by Luisa Klotz). One representative experiment out of two independent 
experiments is shown. * p<0.05; ** p<0.01. 
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4.2.8 PPARγ inhibits T cell-mediated licensing of macrophages 
During EAE, the interaction of encephalitogenic T cells with CNS APCs, i.e. 
macrophages and microglia, does not only lead to reactivation of autoreactive T cells 
but also results in reciprocal activation of macrophages and microglia by 
encephalitogenic T cells, a process referred to as licensing, that leads to further 
aggravation of disease57-60. We hypothesised that activation of PPARγ in myeloid cells 
interferes with T cell-mediated licensing of these cells, which would strongly contribute 
to amelioration of myeloid cell-mediated CNS autimmunity by PPARγ.  
To experimentally address whether PPARγ influences T cell-mediated licensing of 
macrophages, we pretreated BM-Ms with PIO, cocultured them with preactivated 
MOG35-55-specific T cells in the presence of the specific antigen MOG35-55, and 
analysed production of NO, TNF-α, and IL-6, as well as CD40 expression and CCL2 
production after 24 h or 48 h of coculture.  
We observed that upon coculture with activated T cells, macrophages were activated 
and produced high amounts of the neurotoxic mediators NO and TNF-α, as well as the 
proinflammatory cytokine IL-6 (Figure 15a-c). Moreover, macrophages exhibited 
increased expression of CD40 (Figure 15d) and produced high levels of CCL2 
(Figure 15e). Importantly, PPARγ activation in macrophages significantly interfered 
with T cell-mediated licensing, as PIO-treated BM-Ms produced less NO, TNF-α, and 
IL-6 (Figure 15a-c), exhibited decreased expression of CD40 (Figure 15d), and secreted 
significantly reduced amounts of CCL2 (Figure 15e).  
In conclusion, these findings demonstrate that PPARγ in macrophages interfered with 
T cell-mediated licensing which resulted in suppressed production of neurotoxic factors 
and proinflammatory cytokines, decreased upregulation of CD40, and reduced levels of 
CCL2. These data strongly suggest that during EAE, interference of PPARγ with T cell-
mediated licensing ameliorates myeloid-cell-mediated pathology in several ways as this 
suppresses neurotoxic innate immune responses, T cell reactivation potential, and 
further recruitment of inflammatory monocytes. 
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Figure 15  PPARγ  controls T cell-mediated licensing of macrophages.  
BM-Ms were pretreated with 10 µM PIO for 7 days or left untreated (w/o PIO), and cocultured with 
αCD3- and αCD28-activated MOG35-55-specific 2D2 CD4+ T cells in the presence of 20 µg/ml MOG35-55 
at a ratio of (a-d) 10:1 or (e) 1:1 (T cells:BM-Ms). (a) NO production was determined by detecting nitrite 
levels in the supernatant by Griess Assay after 48 h. (b,c) The concentration of (b) TNFα and (c) IL-6 in 
the supernatant was quantified by ELISA after 24 h and 48 h of coculture, respectively. (d) CD40 
expression by CD11b+ BM-Ms was monitored by flow-cytometry after 24 h of coculture. (e) CCL2 
production was determined in the supernatant by ELISA. Shown is one representative experiment out of 
at least two independent experiments. Graphs depict mean results ± SEM. * p<0.05; ** p<0.01; 
***p<0.001. 
4.2.9 Summary of chapter 6.2 
In the present study, we showed that PPARγ activation in vivo resulted in amelioration 
of EAE during the T cell-mediated induction phase and the effector phase. Further 
analysis revealed that amelioration was characterised by a strong reduction in levels of 
inflammatory mediators in the CNS as well as diminished demyelination and axonal 
damage. We demonstrated that PPARγ in myeloid cells, including CNS-resident 
microglia and infiltrating macrophages, limited inflammatory responses of myeloid 
cells during the effector phase of EAE. Importantly, we identified inflammatory 
monocytes as the key myeloid cell population regulated by PPARγ and could show that 
monocytes acquire also a microglia-like phenotype during EAE. In vitro, activation of 
PPARγ suppressed innate immune responses involved in neurotoxicity which limited 
inflammation-induced neurotoxicity mediated by microglial cells. Furthermore, in vivo 
PIO-treatment resulted in reduced expression of MHC-II and CD40 on CNS 
macrophages and microglia and in line with this we observed that local T cell responses 
within the CNS of PIO-treated animals were reduced. Importantly, we showed that 
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PPARγ increased the threshold of myeloid cells towards reciprocal activation of 
myeloid cells by activated T cells leading to dampened innate immune responses of 
myeloid cells after T cell-mediated activation, like the production of NO and TNF-α 
which critically contribute to CNS pathology.  
Taken together, PPARγ is a central regulator of monocyte-mediated CNS pathology 
during autoimmune inflammation which interferes with perpetuation of disease in 
several ways. On the one hand, it modulates local T cell responses by reducing 
expression of surface molecules on CNS myeloid cells as well as cytokines necessary 
for local reactivation of encephalitogenic T cells. On the other hand, PPARγ in myeloid 
cells suppresses reciprocal activation of myeloid cells by activated T cells which results 
in neuroprotection through strongly reduced production of neurotoxic factors. Both 
scenarios result in ameliorated CNS inflammation thus making PPARγ in myeloid cells 
an attractive target for treatment regimes against CNS autoimmunity.  
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5 Discussion 
5.1 Activation of PPARγ  in DCs impairs cross-priming of naive CD8+ 
T cells by upregulation of B7H1  
In the first part of this thesis, we characterised the impact of PPARγ activation in DCs 
on cross-presentation of soluble antigen and subsequent cross-priming of naive CD8+ 
T cells. Treatment with the synthetic PPARγ agonist PIO resulted in upregulation of 
MR expression which in turn led to enhanced MR-mediated uptake of the soluble model 
antigen OVA and, furthermore, increased amounts of cross-presented OVA in vitro and 
in vivo. Importantly, after PPARγ-activation, DCs significantly upregulated the 
coinhibitory molecule B7H1 which impaired activation of naive CD8+ T cells and 
resulted in strongly reduced CD8+ T cell effector functions.  
Burgdorf et al. demonstrated that MR-expressing DCs represent the subpopulation of 
DCs that is capable of cross-presenting soluble OVA25,26 and furthermore, that PPARγ 
is preferentially expressed by MR+ BM-DCs103. Although these data indicate that 
PPARγ might be involved in the general induction of MR expression in DCs, we 
showed in this study that PPARγ is not essential for MR baseline expression as 
PPARγKO and wildtype BM-DCs expressed the MR at comparable levels (Figure 1c+d). 
However, we demonstrated that PPARγ in DCs plays an important role in induction of 
additional MR expression as PIO-mediated activation of PPARγ resulted in significant 
upregulation of the MR. Although the molecular mechanism of PPARγ-mediated 
induction of MR expression has not been investigated in this study, it is tempting to 
speculate that PPARγ-mediated MR upregulation resulted from direct induction of gene 
transcription after binding to a PPAR response element as two putative PPAR response 
elements have been identified in the promotor region of the mannose receptor gene104.  
Importantly, by employing conditional PPARγKO BM-DCs we could demonstrate that 
the observed increase in MR expression and MR-mediated OVA-uptake in DCs was 
mediated by PPARγ-dependent effects of PIO. However, we still observed a slight 
increase in MR expression and OVA uptake in response to PIO-treatment in PPARγKO 
BM-DCs although both was significantly decreased when compared to PIO-treated 
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wildtype BM-DCs: 66.7 % for MR expression (Figure 1c,d) and 79.2 % for OVA 
uptake (Figure 2c,d). As PPARγKO BM-DCs were generated by Cre-mediated 
recombination which has been shown to efficiently ablate PPARγ in 70-80 % of the 
Cre-treated cells121, we hypothsise that the remaining PIO-effect is most probably due to 
incomplete PPARγ ablation.  
Several studies have identified that CD8α+ splenic DCs are the main cross-presenting 
DCs in vivo122 and Burgdorf et al. have shown that the MR is expressed by a 
subpopulation of CD8α+ splenic DCs but not by CD8a- DCs. MR-expression in CD8α+ 
splenic DCs was important for transfer of OVA towards cross-presentation after 
endocytosis25. In the study presented here, we extend these findings by showing that 
PPARγ activation in vivo resulted in an increased proportion of MR-expressing splenic 
DCs (Figure 7a). Although our studies could have suggested that PPARγ also changed 
the proportion of CD8α+ DCs in the spleen, we did not detect any changes in CD8α 
expression by splenic DCs after PIO-treatment in preliminary experiments. Therefore 
we hypothesise that PIO-treatment solely changed the proportion of MR+ splenic DCs 
within the population of CD8α+ DCs.  
PPARγ-activation in BM-DCs in vitro and splenic DCs in vivo resulted in increased 
cross-presentation of OVA as demonstrated by increased activation of the 
costimulation-independent T cell hybridoma B3Z (Figure 3b and Figure 7b). However, 
despite enhanced cross-presentation we observed that naive, OVA-specific CD8+ T cells 
exhibited reduced activation and impaired effector functions (Figure 4a,c and Figure 
7c,d). In a previous study, Klotz et al. have shown that PPARγ inhibits inflammation-
induced upregulation of costimulatory molecules such as CD40, CD80, and CD86 as 
well as production of the proinflammatory cytokine IL-12 which resulted in CD4+ T cell 
anergy79. However, although our data suggested that missing costimulation might also 
be the explanation for impaired activation of naive CD8+ T cells by PIO-treated DCs, 
we show here that in immature DCs PPARγ activation did not significantly alter the 
expression of costimulatory molecules. Instead PIO-treatment significantly enhanced 
coinhibitory signals, i.e. the expression of B7H1, which mediates T cell inactivation by 
signaling via PD-1 expressed by T cells28. Importantly, we identified PIO-mediated 
upregulation of B7H1 in DCs as the key mediator of impaired CD8+ T cell priming after 
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PPARγ activation as naive CD8+ T cells were properly activated when PIO-treated DCs 
were deficient in B7H1 or coculture experiments were performed in the presence of a 
PD-1 blocking antibody. The here presented study reveals a very effective mechanism 
of antigen-specific CD8+ T cell inactivation which is mediated by strongly enhanced 
cross-presentation of antigen and simultaneous increase in coinhibitory signaling, 
namely via B7H1, after activation of PPARγ.  
Under physiological conditions this mechanism of tolerance induction might be induced 
by endogenous PPARγ ligands which include unsaturated fatty acids like linoleic acid 
metabolites generated by the enzyme 12/15 lipoxygenase or 15-deoxy-12,14-
prostaglandin J270. Interestingly, PPARγKO BM-DCs exhibit a strongly increased 
capacity to prime naive CD4+ T cells when compared to PPARγWT BM-DCs79 which 
indicates that endogenous PPARγ ligands could be involved in limiting DC-mediated T 
cell activation. This could potentially restrict excessive T cell activation and influence 
the outcome of T cell-mediated autoimmunity. Up to now, several studies have 
demonstrated a role of PPARγ endogenous ligands in local immune regulation during 
autoimmune inflammation. Emerson et al. demonstrated that ablation of 12/15 
lipoxygenase exacerbated CNS autoimmunity123, which substantiates the hypothesis that 
the presence of endogenous PPARγ ligands is crucial for limiting autoimmune 
inflammation. In line with this, several studies have shown that in vivo substitution of 
the main precursor of these ligands, i.e. linoleic acid, is protective in experimental 
colitis124 and EAE125 and furthermore, that treatment of mice with 15-deoxy-12,14-
prostaglandin J2 during EAE resulted in amelioration of the clinical disease course126. 
Importantly, the TH2 cytokine IL-4 has been described to induce not only PPARγ in 
macrophages but also expression of 12/15 lipoxygenase82. The latter is mediated via 
IL-4-induced binding of signal transducer and activator of transduction 6 (STAT6) to 
STAT6-responsive elements in the promoter region of 12/15 lipoxygenase127. Thus, it is 
conceivable that PPARγ-mediated induction of CD8+ T cell tolerance as described in 
this study provides at least partial explanation for the anti-inflammatory effects 
observed after exposure to IL-4. 
The here presented mechanism of CD8+ T cell inactivation restricts excessive T cell 
responses and might be crucial during late stages of inflammation when the MR is 
upregulated and plays an important role in clearance of self-proteins that are elevated 
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during wound healing97. Although this question has not been investigated in this study, 
it could be speculated that endogenous ligands activate PPARγ at such late timepoints 
of inflammation which would result in PPARγ-induced upregulation of the MR for 
clearance of self-proteins. Without counterregulatory mechanisms, the increase in MR-
expression and subsequent enhanced cross-presentation of endogenous antigens could 
potentially result in activation of self-reactive CD8+ T cells and hence, tissue damage or 
autoimmunity. One such mechanism to interfere with induction of autoimmunity could 
be upregulation of B7H1 after PPARγ activation in DCs which results in protection of 
the organism from CD8+ T cell-mediated pathology.  
Interestingly, we observed the PPARγ-mediated inhibitory effect on cross-presentation 
solely for naive CD8+ T cells as the antigen-specific reactivation of CD8+ memory 
T cells by PIO-treated BM-DCs was not impaired (Figure 4d). Our observation is in line 
with other reports which demonstrated in vitro that reactivation of memory T cells 
depends primarily on signal 1, i.e. antigen presentation, and is independent on signal 2, 
i.e. costimulation128. Importantly, our data extend these findings by the observation that 
activation of memory T cells by professional APCs was independent of coinhibitory 
signaling mediated by upregulation of B7H1. This finding is especially important with 
regard to the development of treatment regimes that aim at dampening autoreactive 
CD8+ T cell responses. Our data suggest that strategies which aim at inducing tolerance 
in CD8+ T cells by PPARγ-mediated increase in B7H1 expression in DCs will prove 
useful in preventing initial priming of CD8+ T cells whereas the reactivation of 
autoreactive memory T cells will not be impaired. In extension of the findings presented 
here, it will be interesting to investigate in conditional PPARγKO BM-DCs whether lack 
of PPARγ is associated with lower expression of B7H1 as reduced coinhibition might 
strongly increase the risk of developing T cell-mediated autoimmunity. In this regard it 
is interesting to note that the expression levels of PPARγ were decreased in peripheral 
blood mononuclear cells (PBMCs) isolated from MS patients compared to healthy 
controls and disease activity was inversely correlated to the expression of PPARγ129. 
With regard to the presented findings we hypothesise that reduced PPARγ levels 
possibly coincide with decreased coinhibition. This would imply that in MS patients, 
PBMCs are more prone to activate autoreactive T cells leading to aggravation of CNS 
autoimmune inflammation. Furthermore, high PPARγ activity in PBMCs might allow a 
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good prognosis for the disease course of MS whereas low PPARγ activity and hence 
low coinhibition might lead to high disease activity. 
Taken together, the presented study demonstrates that PPARγ activation in DCs results 
in induction of CD8+ T cell tolerance which is mediated by strongly increased cross-
presentation of antigen and concomitant enhanced signaling via B7H1. This molecular 
mechanism of CD8+ T cell inactivation might open new possibilities for the 
development of treatment regimes designed to impede CD8+ T cell-mediated 
autoimmune diseases. 
5.2 PPARγ  is a regulator of myeloid cell immunogenicity and a 
potential candidate for treatment of MS 
In the second part of this thesis we investigated the role of PPARγ in myeloid cells 
during EAE. Treatment with the PPARγ-agonist PIO resulted in amelioration of clinical 
and histopathological signs of EAE and we demonstrated that PPARγ in myeloid cells is 
important for limiting CNS inflammation during the effector phase of EAE. 
Importantly, we identified inflammatory monocytes as the central myeloid cell 
population regulated by PPARγ. In vivo PPARγ activation in CNS myeloid cells 
suppressed the upregulation of CD40 and MHC-II during the effector phase of EAE and 
in line with this we observed reduced CD4+ T cell responses within the CNS of PIO-
treated mice. Importantly, PPARγ in myeloid cells also suppressed the reciprocal 
activation of myeloid cells by autoreactive T cells resulting in diminished innate 
effector functions and thus, attenuated neuroinflammatory responses. 
Daily treatment of EAE-diseased mice with the synthetic PPARγ agonist PIO resulted in 
a milder course of disease during the T cell-mediated induction phase and the effector 
phase (Figure 8a) during which inflammatory monocytes play a disease-promoting role 
by production of proinflammatory cytokines and  proteolytic enzymes63. This is in line 
with previous findings which demonstrate that PPARγ agonists are effective in 
ameliorating disease in models of monophasic and relapsing EAE74,90,126 and further 
underlines that PPARγ agonists provide therapeutic benefit in CNS autoimmunity.  
During the effector phase, we observed a reduction in proinflammatory cytokines and 
iNOS in the CNS (Figure 8b) indicating that PIO-treatment beneficially alters the 
inflammatory milieu during EAE which contributes to amelioration of disease by 
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decreasing neuroinflammation. Among the investigated proinflammatory mediators, we 
observed a strong reduction in TNF-α and iNOS expression which strongly contribute 
to neurotoxicity61. TNF-α has been shown to be a major effector of immune-mediated 
demyelination as mice that constitutively express TNF-α within the CNS spontaneously 
develop a chronic inflammatory demyelinating disease130. As TNF-α and iNOS are 
primarily produced by CNS-resident microglia and infiltrating macrophages49, PPARγ 
activation in myeloid cells has probably contributed to this reduction. Furthermore, 
IL-12 and IL-23, cytokines important for the reactivation of TH1 and TH17 cells, 
respectively27,29, were found to be reduced in the CNS and concomitantly, we observed 
that levels of the T cell cytokine IFN-γ were diminished, thus indicating that in vivo 
PPARγ activation interfered with local T cell responses.  
In addition, we could show that in the CNS of PIO-treated animals chemokines, 
including CCL2, CCL3, and CXCL10, were significantly reduced (Figure 11d) and in 
line with this, strongly reduced numbers of macrophages and T cells were present in the 
CNS at a late stage of EAE (Figure 11f). Chemokines play an important role during MS 
and EAE, as the production of chemokines within the CNS results in further recruitment 
of encephalitogenic T cells, B cells, and inflammatory monocytes which in turn leads to 
perpetuation of local inflammation and subsequent neurodegeneration. Interfering with 
chemokine-dependent immune cell recruitment has proven to be effective in 
amelioration of CNS inflammation63,131-133 and strategies that have been developed 
include antibodies against chemokines, small molecules that prevent binding of the 
chemokine to its receptor, as well as mutant chemokines that act as chemokine receptor 
antagonists131. It is conceivable that treatment regimes that interfere with the 
recruitment of a range of immune cells will prove more effective than those that target 
just one cell population. Here, we identified PPARγ as an attractive candidate to 
modulate immune cell recruitment to the CNS during ongoing inflammation as PIO-
treatment resulted in reduced expression of a variety of chemokines, which interferes 
with recruitment of monocytes, macrophages as well as activated T cells during already 
established CNS autoimmunity.  
Among the investigated chemokines, especially CCL2 plays an important role in EAE. 
Mice that lack the CCL2 receptor CCR2 are resistant to EAE134 and Mildner et al. 
identified CCR2+ inflammatory monocytes to be essential for development of EAE and 
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crucial for cell-mediated pathology during the effector phase of EAE63. In active EAE, 
the expression of CCL2 correlates with disease severity135 and CCL2-deficient mice 
show a delayed onset of disease as well as ameliorated clinical symptoms136. 
Furthermore, interference with CCL2-mediated recruitment of inflammatory monocytes 
has been shown to be beneficial during the effector phase of EAE63 and in a model of 
west nile virus encephalomyelitis118. Importantly, we identified myeloid cells as a 
potential source for CCL2 in the CNS and demonstrated that PPARγ suppressed the 
production of CCL2 by myeloid cells upon interaction with activated T cells 
(Figure 15e). Hence, PPARγ in myeloid cells modulates innate immune responses 
during EAE not only in a qualitative but also in a quantitative manner. Interestingly, 
CCL20 which attracts T cells was only slightly reduced in PIO-treated animals. CCL20 
has been shown to be constitutively expressed on epithelial cells of the choroids plexus 
in healthy mice which is important for the entry of CCR6-expressing TH17 cells into the 
brain and the onset of EAE55. As the induction phase is also ameliorated in PIO-treated 
animals, it is possible that CCL20 is regulated by PPARγ but to an earlier timepoint, 
namely during the T cell-dependent phase when TH17 cells are recruited to the CNS.  
By employing myeloid cell-specific conditional knockout (LysM-PPARγKO) mice we 
demonstrated that PPARγ in myeloid cells, i.e. macrophages and microglia, is primarily 
important during the effector phase of EAE, as LysM-PPARγKO mice exhibited an 
aggravated disease course during the effector but not the induction phase when 
compared to wildtype mice (Figure 9b). This lack of effect during the induction phase is 
surprising as our group has previously shown that ablation of PPARγ in DCs results in 
enhanced CD4+ T cell responses79 and PPARγKO macrophages are involved in 
peripheral induction of T cell responses. This indicates that PPARγ in peripheral 
myeloid cells does not play a role in regulating initial T cell responses during EAE. 
However, it is also conceivable that APCs that are not targeted by LysM-Cre-mediated 
ablation of PPARγ, most probably DCs, are involved in initial T cell priming whereas 
LysM-expressing myeloid cells only play a minor role.  
In a previous study we showed that conditional CD4-PPARγKO mice exhibit an 
aggravated disease course during the T cell-mediated induction but not the effector 
phase which was due to enhanced initial TH17 responses89. Thus, by employing cell-
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type specific ablation of PPARγ in different immune cells that play a role during EAE, 
we revealed that PPARγ interferes at different stages of CNS autoimmunity depending 
on the cell type involved. In T cells PPARγ plays a role in limiting the induction phase 
of EAE. In contrast, PPARγ in myeloid cells is an important regulator during the 
effector phase when it limits local inflammatory responses and hence, CNS pathology. 
Importantly, we identified CCR2+ inflammatory monocytes as the central myeloid cell 
population that is regulated by PPARγ during the effector phase of EAE. Upon 
depletion of CCR2+ monocytes by administration of an αCCR2 antibody, we observed 
that EAE was ameliorated in both, wildtype and LysM-PPARγKO mice, as described 
before63 and furthermore, that ablation of inflammatory monocytes resulted in 
abrogation of the differences observed between wildtype and LysM-PPARγKO mice 
during EAE (Figure 9d). This observation further underlines the importance of 
inflammatory monocytes for EAE pathogenesis in general and furthermore, 
demonstrates that inflammatory monocytes represent the key myeloid cell population 
regulated by PPARγ. Interestingly, our findings indicate that although PPARγKO 
microglia potentially contribute to the aggravation of disease, PPARγKO microglia alone 
are not sufficient to mediate the damage. There are two reasons why this might be the 
case. Firstly, infiltrating macrophages are important for full activation of microglia as 
the absence of blood-borne macrophages, e.g. after depletion by clodronate liposomes, 
was shown to result in impaired activation of microglia in several studies of EAE49,60,68. 
Hence, as in αCCR2-treated LysM-PPARγKO mice, numbers of infiltrating 
macrophages in the CNS are low63, PPARγKO microglia might not have been 
appropriately activated which resulted in diminished microglial inflammatory responses 
and hence, abolished any microglia-mediated differences between LysM-PPARγKO and 
LysM-PPARγWT mice. Secondly, infiltrating Ly-6Chi monocytes have been shown to 
differentiate not only into CNS macrophages but also acquire a microglia-like 
phenotype under certain conditions such as in a model of West Nile virus 
encephalitis118. A prerequisite for this differentiation process is an overt blood-brain 
barrier disruption137 whereas under steady-state conditions CNS-resident microglia 
reside in the CNS from birth where they self-renew rather than being replaced by bone 
marrow-derived progenitors138. Importantly, here we show by in vivo labelling of 
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Ly-6ChiCCR2+ inflammatory monocytes and adoptive transfer of monocytes that during 
EAE, inflammatory monocytes invade the brain where they differentiate into 
macrophages and microglia. These data suggest that the absence of monocyte-to-
microglia-differentiation processes in αCCR2-treated animals could also have 
contributed to the abrogated difference between LysM-PPARγKO and LysM-PPARγWT 
mice after depletion of inflammatory monocytes. 
Several reports describe that the activation of PPARγ in macrophages and microglia 
results in inhibition of inflammatory responses upon activation in vitro69,73,80,81. In line 
with these, we observed that PPARγ in macrophages and microglia interfered with the 
production of neurotoxic factors like TNF-α, NO, and ROS as well as proinflammatory 
cytokines and importantly, suppressed inflammation-induced neurotoxicity 
(Figures 11,12). These in vitro findings mirrored our in-vivo observation that reduced 
levels of inflammatory mediators were present during the effector phase within the CNS 
of PIO-treated animals and further indicate that the observed reduction in neuronal 
damage in the CNS of PIO-treated animals was at least in parts due to a modulation of 
myeloid cell immunogenicity. The molecular mechanisms that mediate the 
antiinflammtory effects of PPARγ have not been subject to this study as this issue has 
already been extensively studied. The primary mechanism by which PPARγ mediates its 
antiinflammatory action is intranuclear crosstalk with other proinflammatory 
transcription factors, such as NF-κB, which results in inhibition of these transcription 
factors and hence, inhibition of gene transcription. This mechanism of action, i.e. the 
ability of a nuclear receptor to inhibit the activity of a promotor without directly binding 
to it, is referred to as transrepression69. Recently, Glass et al. identified the molecular 
pathway by which PPARγ is converted into a promotor-specific repressor of NF-κB 
target genes that regulate immunity and homeostasis. They revealed that ligand-
dependent sumoylation directs PPARγ to the promoters of inflammatory genes where it 
inhibits transcription by stabilising NCoR-containing corepressor complexes at the 
promotor. As a result, these complexes are not cleared from the promoter and target 
genes are maintained in a repressed state139.  
During EAE, myeloid cells substantially contribute to neuropathology not only by 
exerting innate effector functions that induce neurotoxicity but also by reinforcing 
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adaptive immune responses as APCs. Here, we revealed that PPARγ in macrophages 
and microglia is important to limit CD4+ T cell responses within the CNS as PIO-
treatment resulted in reduced expression of MHC-II on macrophages and microglia as 
well as of the costimulatory molecule CD40 on macrophages (Figure 13). Importantly, 
this effect was PPARγ-dependent, as in PIO-treated LysM-PPARγKO mice we did not 
observe a reduction of CD40 or MHC-II expression on CNS-infiltrating macrophages.  
Both, MHC-II and CD40, are crucial for local restimulation of encephalitogenic 
CD4+ T cells within the CNS as MHC-II is important for presentation of self-antigens to 
autoreactive CD4+ T cells40,51 and CD40 has been demonstrated to critically influence 
the outcome of EAE51,58,59. Our data suggest that PPARγ-mediated suppression of 
MHC-II and CD40 expression on CNS macrophages and microglia is responsible for 
reduced reactivation of autoreactive T cells (Figure 14). Importantly, it has been shown 
that T cell-derived IFN-γ induces MHC-II expression on myeloid cells which 
contributes to perpetuation of local CD4+ T cell responses60,140-142. Our data indicate that 
reduced reactivation of CD4+ T cells and diminished IFN-γ production, respectively, in 
PIO-treated animals contributes to keeping MHC-II expression levels low and, hence, 
also presentation of self-antigens. Interestingly, also microglial MHC-II expression was 
strongly reduced by PIO-treatment although PIO has been shown to exhibit only limited 
permeability to cross the BBB under steady-state conditions143. Although it is 
conceivable that this permeability increases during ongoing CNS inflammation due to 
leakage of the BBB, microglial immune responses could also be modulated indirectly. 
As microglia are activated upon interaction with infiltrating macrophages49,60,68 and 
activated T cells56,57 which are both targeted in the periphery by oral PIO-treatment, 
infiltrating immune cells which exhibit a PPARγ-mediated less stimulatory phenotype, 
do not fully activate CNS-resident microglia. Furthermore, as we could show that 
inflammatory monocytes also exhibit a microglial phenotype after entry into the 
inflamed CNS (Figure 10), peripheral modulation of monocyte activation by PIO-
treatment will also influence the immunogenicity of the microglial cell population 
within the CNS. Therefore, PIO is able to indirectly interfere with microglial immune 
responses despite its limited permeability to cross the BBB. The costimulatory molecule 
CD40 on CNS macrophages and microglia has been shown to be crucial for the 
amplification of CNS autoimmunity as CD40 knockout mice are resistant to EAE58. 
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Furthermore, treatment of diseased mice with an antibody against CD40L on day 13 
after immunisation results in amelioration of disease demonstrating that the interaction 
of CD40 and CD40L plays an important role in the initiation of EAE but also during the 
effector phase58,59. Hence, our data suggest that PIO-treatment interferes with local 
reactivation of encephalitogenic T cells also by suppression of myeloid cell 
costimulation. This leads to a decrease in T cell effector functions and thus, 
amelioration of disease. 
In this line, we observed in the CNS of PIO-treated animals not only a reduction in 
expression levels of MHC-II and CD40 on CNS myeloid cells but moreover, decreased 
levels of IL-12 and IL-23, two cytokines that are important for local reactivation of TH1 
and TH17 cells, respectively (Figure 8,13). Accordingly, we observed a reduction in 
both, IFN-γ-expressing TH1 cells and IL-17A-expressing TH17 cells during the effector 
phase of EAE demonstrating that autoreactive CD4+ T cell responses were decreased in 
the CNS of PIO-treated mice. However, the reduction was more pronounced on 
TH17 cells than TH1 responses. This differential effect might be explained by additional 
direct actions of PPARγ on TH17 development. We have previously shown that PPARγ 
acts as a cell-intrinsic regulator of TH17 differentiation which suppressed TH17 
development in vitro and during EAE in vivo89. However, as the TH1 response is 
reduced in the CNS of PIO-treated mice and moreover, autoreactive T cells need to be 
locally reactivated within the CNS40, our data suggest that the PIO-mediated reduction 
in local T cell responses is largely mediated by modulation of CNS APCs and their 
cytokine milieu.  
During CNS inflammation myeloid cells interact with T cells in two directions. On the 
one hand, myeloid cells provide necessary signals which lead to reactivation of 
encephalitogenic T cells58. On the other hand, myeloid cells reciprocally receive signals 
of activated T cells through soluble mediators like IFN-γ or GM-CSF56,57 or cell-cell 
interactions e.g. via CD40L58,59, which is referred to as T cell-mediated licensing. 
Importantly, in this study we identified that PPARγ in myeloid cells limits such T cell-
mediated licensing which resulted in ameliorated immune responses, such as production 
of NO, TNF-α, IL-6, and CCL2 as well as reduced CD40 expression (Figure 15). We 
therefore hypothesise that PPARγ represents a cell-intrinsic brake that limits the 
inflammatory activation of myeloid cells by autoreactive T cells during CNS 
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autoimmunity and that interference with local T cell-mediated licensing of myeloid cells 
during EAE will ameliorate local innate immune responses within the CNS and hence 
disease progression.  
Taken together, during ongoing CNS autoimmune inflammation the interaction of 
myeloid cells and encephalitogenic T cells is crucial for the perpetuation of disease. 
CNS myeloid cells locally reactivate encephalitogenic T cells to perform adaptive 
effector functions by antigen-presentation via MHC-II and providing sufficient 
costimulation by signalling through CD40 (Figure 16 (1)) while at the same time, 
T cell-mediated licensing of CNS myeloid cells elicits local innate immune responses 
which critically contribute to autoimmune inflammation and CNS damage 
(Figure 16 (2)). Both steps are not independent but rather fuel each other, resulting in an 
amplification and fortification of autoimmune inflammation during CNS autoimmunity. 
As interference with the immunogenic potential of CNS myeloid cells dampens both, 
T cell reactivation and T cell-mediated myeloid cell licensing, specific targeting of 
intrinsic myeloid cell activity represents a very effective strategy to interefere with 
reciprocal interaction of autoreactive T cells and CNS myeloid cells. Importantly, in this 
study we identified PPARγ as a promising candidate for such targeted modulation of 
CNS myeloid cell immunogenicity. 
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Figure 16 During EAE, PPARγ  in myeloid cells interferes with both axes of myeloid : T cell 
interaction. 
During EAE myeloid cells interact with encephalitogenic T cells via MHC-II and CD40 and through 
secretion of proinflammatory cytokines which results in local T cell reactivation and reinforcement of 
adaptive immune responses (1). Autoreactive T cells reciprocally license myeloid cells to perform innate 
effector functions, such as production of NO and ROS or secretion of proinflammatory cytokines 
including TNF-α, all of which results in neurotoxicity and hence, CNS pathology (2). Importantly, 
PPARγ in myeloid cells interferes at both steps of this vicious circle, i.e. T cell reactivation and innate 
neurotoxic responses by myeloid cells, which leads to amliorated CNS autoimmune inflammation.  
 
Macrophages in MS or EAE lesions have been shown to exhibit a classically activated 
phenotype that has been linked to neurotoxicity due to high production of TNF-α, NO, 
ROS, and proinflammatory cytokines61. In this study we demonstrated that PPARγ 
activation in macrophages and microglia resulted in reduced expression of these 
inflammatory mediators in response to stimulation which resembles characteristics 
associated with the status of alternatively activated macrophages (aaMs). aaMs are 
induced by TH2 cytokines IL-4 and IL-13, express several characteristic markers, such 
as arginase-I, YM1, and IGF-1, and play important roles in the maintenance of tissue 
homeostasis and wound healing144. Preliminary experiments showed that under steady-
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state conditions, oral treatment with PIO resulted in increased expression of the aaM-
associated markers arginase-I, Ym1, and FIZZ in peritoneal macrophages, splenic 
monocytes, and blood monocytes. These preliminary data suggest that pharmacological 
activation of PPARγ indeed induces an aaM-phenotype in myeloid cells rather than 
simply suppressing the expression of markers, such as TNF-α and iNOS, which have 
been associated with classically activated macrophages. This observation is especially 
interesting with regard to the development of novel treatment regimes as several reports 
have demonstrated beneficial roles for alternatively activated (aa) myeloid cells in 
immune modulation of CNS autoimmunity. Butovsky et al. demonstrated that the 
intraventricular injection of IL-4-treated microglia, which express markers of aaMs, 
significantly improves clinical symptoms of EAE and induces oligodendrogenesis in the 
CNS145. Furthermore, Weber et al. demonstrated that monocytes treated with glatiramer 
acetate, an approved drug for MS-treatment, promote the development of aa monocytes 
that suppress the development of TH17 cells and induced both, TH2 differentiation and 
expansion of regulatory T cells during EAE146. Therefore, it would be interesting to 
investigate in future experiments whether PPARγ activation in myeloid cells during 
EAE induces aa monocytes, macrophages, and microglia and to what extent this 
contributes to PIO-mediated amelioration of EAE. Importantly, several studies indicate 
that PPARγ is important for the development of aaMs147. Odegaard et al.148 
demonstrated in murine macrophages that PPARγ is required for acquisition and 
maintenance of the aa phenotype and that IL-4 induced expression of aa markers in a 
PPARγ-dependent manner. Importantly, Bouhlel et al.149 reported that activation of 
PPARγ in human monocytes results in polarisation to an aa phenotype thus indicating 
that treatment with a PPARγ agonist during EAE might indeed be able to alter the 
phenotype of monocytes towards an aaM phenotype before they enter the inflamed 
CNS. However, more experiments need to be performed to further address this issue. 
Especially analysis of the expression profile of macrophages and microglia isolated 
from the CNS of PIO-treated EAE-diseased animals would be of interest to confirm a 
PPARγ-mediated induction of aa macrophages in vivo in the context of CNS 
autoimmunity.  
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5.3 Concluding remarks 
It is known that PPARγ plays an important role in regulation of inflammatory responses 
by different immune cells including DCs, macrophages, and microglia69. In the first part 
of this study we extend previous findings which showed that activation of PPARγ in 
DCs induces CD4+ T cell anergy79 as we now demonstrate that PPARγ in DCs also 
regulates cross-priming of CD8+ T cells resulting in impaired activation of naive 
CD8+ T cells. Furthermore, we revealed that during EAE, PPARγ limits myeloid 
cell-mediated CNS pathology by interfering with the T cell reactivating capacity of 
CNS macrophages and microglia but also by suppressing innate immune responses 
upon T cell-mediated licensing of myeloid cells. Thus, both parts of the study further 
underline that PPARγ is an attractive pharmacological target to treat diseases which are 
mediated by excessive T cell responses or innate inflammation.  
In DCs, PPARγ activation increased MR expression and MR-mediated uptake of the 
model antigen OVA. Despite significant elevated levels of cross-presented OVA, 
activation of naive OVA-specific CD8+ T cells was impaired due to concomitant 
upregulation of the coinhibitory molecule B7H1 (Figure 16). This mechanism of action 
interferes with excessive CD8+ T cell activation and might be crucial e.g. during late 
stages of inflammation when the MR is upregulated and plays an important role in the 
clearance of self-proteins that are elevated during wound healing97. MR-mediated 
increase of cross-presented self-antigen could favour the activation of self-reactive 
CD8+ T cells and hence, tissue damage. However, concomitant upregulation of the 
coinhibitory molecule B7H1 interferes with such activation and protects the organism 
from CD8+ T cell-mediated tissue damage and autoimmunity. 
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Figure 17 Increased antigen cross-presentation but impaired cross-priming after activation of 
PPARγ  in DCs is mediated by upregulation of B7H1.  
PIO-treatment results in increased expression of levels of the MR by DCs that results in enhanced 
MR-mediated uptake and cross-presentation of the model antigen OVA. Due to strongly increased 
expression of the coinhibitory molecule B7H1, activation of naive OVA-specific CD8+ T cells is 
impaired.  
 
In myeloid cells, PPARγ is important to limit local immune responses during the 
effector phase of EAE. We identified CCR2+ inflammatory monocytes as the key 
population regulated by PPARγ which are recruited to the inflamed CNS during EAE 
where they differentiate into macrophages but also acquire a microglia phenotype 
(Figure 17, (1)). PPARγ suppresses reactivation of encephalitogenic T cells by 
decreasing MHC-II and CD40 expression on CNS myeloid cells as well as production 
of cytokines important for reactivation of TH1 and TH17 cells (Figure 17, (2+3)). 
Importantly, PPARγ also interferes with reciprocal licensing of myeloid cells by 
activated T cells resulting in decreased innate effector functions, such as production of 
proinflammatory cytokines and chemokines (Figure 17, (4)) and in consequence reduces 
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inflammation-induced neurotoxicity (Figure 17, (5)). Thus, pharmacological activation 
of PPARγ in myeloid cells during EAE controls the immunogenic capacity of CNS 
myeloid cells which contributes to amelioration of EAE in two ways: First, by 
impairing reactivation of autoreactive T cells by myeloid cells and second, by 
interfering with T cell-mediated licensing of myeloid cells. Hence, PPARγ represents a 
brake that limits the mutual interactions between myeloid cells and encephalitogenic 
T cells within the CNS.  
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Figure 18 PPARγ  is an important regulator of myeloid cell-mediated CNS pathology during 
the effector phase of EAE.  
During EAE, pharmacological activation of PPARγ by PIO-treatment results in amelioration of disease in 
several ways:                     
(1) Reduced levels of chemokines interfere with recruitment of inflammatory monocytes and autoreactive 
T cells.                      
(2) PIO-treatment reduced the potential of myeloid cells to reactivate autoreactive T cells due to reduced 
levels of MHC-II and CD40 expression which                 
(3) results in less T cell activation.                            
(4) Importantly, PPARγ suppresses T cell-mediated activation of myeloid cells.               
(5) This dampens innate immune responses that mediate neurotoxicity, hence, mediating protection.  
 
Taken together, both studies demonstrate that PPARγ in myeloid cells is an attractive 
pharmaceutical target for treatment of excessive immune responses such as those 
observed during autoimmunity. Furthermore, both studies show that activation of 
PPARγ in innate immune cells has beneficial effects on different stages of such 
(auto-)immune responses, i.e. PPARγ activation interferes with the initial T cell 
responses but also limits local reactivation of autoreactive T cells and innate effector 
functions. This is important with regard to treatment of already established T cell 
autoimmunity as this will allow treatment also after onset of disease. Importantly, in 
contrast to treatment regimes which aim at interfering with the activation or 
differentiation of certain autoreactive T cells and depend on antigen recognition, 
activation of PPARγ in innate APCs leads to antigen-independent amelioration of 
disease due to a general decrease of their inflammatory potential. Importantly, 
PPARγ-mediated dampening of innate effector functions mediates protection against 
innate immune cell-mediated tissue damage. 
So far, PPARγ agonists currently approved for treatment of human type 2 diabetes, such 
as PIO or rosiglitazone, have been demonstrated to be beneficial in a number of 
autoimmune and other inflammatory diseases, including EAE, inflammatory bowel 
disease, or psoriasis. However, although PPARγ ligands are generally proved to be safe, 
they exhibit different undesired metabolic adverse effects, such as fluid retention, 
peripheral oedema, and heart failure84. As the metabolic action of PPARγ is mainly 
mediated by binding to PPAR response elements in the promotor region of target genes, 
the development of new PPARγ agonists should be promoted that specifically activate 
PPARγ to perform immunemodulatory actions that are preferentially mediated by 
negative interference with proinflammatory transcription factors69. The identification of 
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ligands that preferentially promote antiinflammatory actions could contribute to 
reducing the metabolic side effects. In line with this, as PIO has been shown to exhibit 
only limited permeability across the BBB143, it would be of great importance to identify 
such PPARγ ligands that can easily cross the BBB to aim at amelioration during CNS 
autoimmunity. 
Taken together, the presented data shed new light on PPARγ-mediated immune 
regulation and will further help to develop new therapeutic strategies to treat excessive 
immune responses such as those observed in autoimmune diseases. 
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